

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1003 10031122 (USA/48/M)*	Placebo	Dose 2/77	05NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Chills	
C4591001 1005 10051341 (USA/23/F)	Placebo	Dose 1/2	22OCT2020		Neg/Pos/Neg	New or increased cough	Pos/
						New or increased shortness of breath	
						New loss of taste or smell	
						Sore throat	
						Diarrhea	
C4591001 1005 10051403 (USA/66/F)	BNT162b2 (30 µg)	Dose 1/4	07NOV2020		Neg/Neg/Unk	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061012 (USA/53/M)*	Placebo	Dose 2/68	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased shortness of breath	
						New or increased muscle pain	
C4591001 1006 10061066 (USA/39/F)*	Placebo	Dose 2/59	11NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1006 10061084 (USA/27/F)*	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
C4591001 1006 10061091 (USA/20/F)*	Placebo	Dose 2/50	30OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061114 (USA/21/M)*	Placebo	Dose 2/35	20OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased muscle pain	
						New loss of taste or smell	
						Sore throat	
C4591001 1007 10071407 (USA/41/M)	Placebo	Dose 1/12	02NOV2020		Neg/Neg/Unk	New or increased cough	Pos/
						Sore throat	
						Diarrhea	
C4591001 1007 10071409 (USA/13/M)	BNT162b2 (30 µg)	Dose 1/10	31OCT2020	04NOV2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1008 10081011 (USA/55/F)*	Placebo	Dose 2/52	22OCT2020	31OCT2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1008 10081048 (USA/38/F)*	Placebo	Dose 2/60	07NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Chills	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081130 (USA/52/F)*	Placebo	Dose 2/32	17OCT2020	29OCT2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/ shortness of breath
C4591001 1008 10081214 (USA/62/M)*	Placebo	Dose 2/42	09NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1008 10081319 (USA/79/F)*	Placebo	Dose 2/31	04NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/ Chills
C4591001 1008 10081338 (USA/53/M)	Placebo	Dose 2/1	06OCT2020	16OCT2020	Neg/Neg/Neg	Fever	Pos/ New or increased cough Chills New or increased muscle pain Sore throat

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081356 (USA/63/M)*	Placebo	Dose 2/25	31OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1008 10081529 (USA/38/M)	BNT162b2 (30 µg)	Dose 1/2	26SEP2020		Neg/Neg/Pos	New or increased cough New loss of taste or smell Sore throat	Pos/
C4591001 1008 10081580 (USA/38/M)	Placebo	Dose 2/7	03NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1008 10081639 (USA/63/M)	Placebo	Dose 1/6	24OCT2020		Neg/Neg/Unk	New or increased cough Sore throat	Pos/
C4591001 1008 10081721 (USA/37/F)	Placebo	Dose 1/13	10NOV2020		Neg/Neg/Unk	Sore throat	Pos/
C4591001 1009 10091128 (USA/51/M)*	Placebo	Dose 2/30	15OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1009 10091211 (USA/44/F)	Placebo	Dose 1/19	03NOV2020		Neg/Neg/Unk	New loss of taste or smell Sore throat New or increased cough Chills	Pos/
C4591001 1009 10091257 (USA/21/F)	Placebo	Dose 1/10	05NOV2020		Neg/Neg/Unk	Sore throat New or increased cough New or increased shortness of breath Chills	Pos/
C4591001 1011 10111174 (USA/24/M)	Placebo	Dose 2/7	04NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1013 10131288 (USA/53/M)*	Placebo	Dose 2/11	25SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat New or increased cough New or increased shortness of breath Chills	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1013 10131475 (USA/49/F)*	Placebo	Dose 2/23	22OCT2020	25OCT2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased muscle pain Sore throat	Pos/
C4591001 1013 10131670 (USA/41/M)†	BNT162b2 (30 µg)	Dose 1/4	11OCT2020		Neg/Pos/Neg	New loss of taste or smell	Pos/
C4591001 1016 10161003 (USA/23/F)*	Placebo	Dose 2/57	14OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1016 10161004 (USA/51/F)*	BNT162b2 (30 µg)	Dose 2/58	15OCT2020	22OCT2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell New loss of taste or smell Sore throat	Pos/
C4591001 1016 10161017 (USA/18/F)*	Placebo	Dose 2/19	07SEP2020		Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161035 (USA/70/F)*	Placebo	Dose 2/67	29OCT2020	29OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/
C4591001 1016 10161048 (USA/52/F)*	Placebo	Dose 2/75	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1016 10161183 (USA/31/F)*	Placebo	Dose 2/32	16OCT2020	01NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/ (R1 Pos)
C4591001 1016 10161207 (USA/62/F)*	Placebo	Dose 2/27	14OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/
						New or increased muscle pain	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161305 (USA/16/M)	Placebo	Dose 2/8	09NOV2020		Neg/Neg/Pos	Sore throat New or increased cough	Pos/
C4591001 1016 10161316 (USA/15/M)	Placebo	Dose 1/17	01NOV2020		Neg/Neg/Unk	New loss of taste or smell New or increased cough	Pos/
C4591001 1016 10161319 (USA/12/F)	Placebo	Dose 2/6	09NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/
C4591001 1016 10161341 (USA/44/F)	BNT162b2 (30 µg)	Dose 1/10	31OCT2020		Neg/Neg/Pos	New or increased cough Chills New loss of taste or smell Sore throat New or increased shortness of breath	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1018 10181198 (USA/50/F)*	Placebo	Dose 2/55	04NOV2020	05NOV2020	Neg/Neg/Neg	Sore throat Diarrhea Fever	Pos/
C4591001 1019 10191038 (USA/47/F)*	Placebo	Dose 2/61	03NOV2020		Neg/Neg/Neg	New or increased cough Fever	Pos/
C4591001 1019 10191184 (USA/52/M)*	Placebo	Dose 2/36	05NOV2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased cough	Pos/
C4591001 1024 10241130 (USA/65/M)†	Placebo	Dose 1/9	28OCT2020		Neg/Neg/Pos	New or increased muscle pain Vomiting Fever	Pos/
C4591001 1028 10281038 (USA/53/F)*	Placebo	Dose 2/31	10OCT2020	22OCT2020	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/
						New or increased cough	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1028 10281100 (USA/47/F)*	Placebo	Dose 2/19	11OCT2020		Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1028 10281132 (USA/61/M)*	Placebo	Dose 2/14	11OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1028 10281138 (USA/38/F)*	Placebo	Dose 2/25	23OCT2020		Neg/Neg/Neg	Sore throat Fever Chills Sore throat Diarrhea	Pos/
C4591001 1028 10281193 (USA/60/F)	Placebo	Dose 2/7	14OCT2020	09NOV2020	Neg/Neg/Neg	New or increased cough Chills	Pos/
C4591001 1028 10281229 (USA/45/M)	Placebo	Dose 2/3	17OCT2020		Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1028 10281250 (USA/18/M)	Placebo	Dose 1/11	18OCT2020		Neg/Neg/Pos	Vomiting Sore throat	Pos/
C4591001 1028 10281294 (USA/23/F)	Placebo	Dose 1/7	04NOV2020		Neg/Neg/Unk	New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1036 10361078 (USA/20/M)	Placebo	Dose 2/2	01OCT2020		Neg/Neg/Pos	New loss of taste or smell	Pos/
C4591001 1037 10371036 (USA/62/M)*	Placebo	Dose 2/52	31OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills	Pos/
C4591001 1037 10371280 (USA/58/M)*	Placebo	Dose 2/28	10NOV2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1038 10381051 (USA/69/M)*	Placebo	Dose 2/51	07NOV2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1038 10381103 (USA/43/F)	Placebo	Dose 2/5	04OCT2020		Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1039 10391021 (USA/26/F)	Placebo	Dose 1/1	25AUG2020	14SEP2020	Neg/Pos/Pos	Fever New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat	Pos/
C4591001 1039 10391025 (USA/55/F)*	Placebo	Dose 2/40	25OCT2020	03NOV2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/
C4591001 1046 10461058 (USA/44/F)*	Placebo	Dose 2/62	09NOV2020		Neg/Neg/Neg	New or increased muscle pain	Pos/
C4591001 1047 10471024 (USA/63/F)*	BNT162b2 (30 µg)	Dose 2/37	16OCT2020	18OCT2020	Neg/Neg/Neg	Fever Diarrhea Vomiting	Pos/
C4591001 1047 10471252 (USA/63/M)	Placebo	Dose 1/22	12OCT2020		Neg/Neg/Unk	Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1068 10681033 (USA/65/M)	Placebo	Dose 1/23	15SEP2020	21OCT2020	Neg/Neg/Pos	New or increased cough New or increased shortness of breath New or increased muscle pain Diarrhea Fever	Pos/
C4591001 1068 10681082 (USA/58/M)*	Placebo	Dose 2/42	01NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Diarrhea Fever	Pos/
C4591001 1068 10681110 (USA/30/F)*	Placebo	Dose 2/22	16OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Sore throat New or increased cough New loss of taste or smell	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1071 10711022 (USA/47/M)*	Placebo	Dose 2/72	10NOV2020		Neg/Neg/Neg	Fever Chills New or increased muscle pain Sore throat	Pos/
C4591001 1071 10711058 (USA/72/F)*	Placebo	Dose 2/60	06NOV2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1071 10711216 (USA/64/F)	Placebo	Dose 1/4	12OCT2020	17OCT2020	Neg/Neg/Unk	Fever New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/
C4591001 1071 10711228 (USA/66/F)	BNT162b2 (30 µg)	Dose 2/5	09NOV2020		Neg/Neg/Pos	Fever New or increased cough	Pos/
C4591001 1072 10721051 (USA/47/F)	Placebo	Dose 1/12	06SEP2020	20SEP2020	Neg/Neg/Unk	Fever New or increased cough	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1072 10721057 (USA/70/M)*	Placebo	Dose 2/41	26OCT2020		Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/
C4591001 1077 10771195 (USA/73/F)*	Placebo	Dose 2/40	01NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1079 10791046 (USA/55/F)*	Placebo	Dose 2/62	26OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1079 10791054 (USA/28/F)*	Placebo	Dose 2/63	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1079 10791162 (USA/20/M)	Placebo	Dose 2/45	09OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1081 10811151 (USA/79/F)*	Placebo	Dose 2/10	30SEP2020	14OCT2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1082 10821016 (USA/46/F)*	Placebo	Dose 2/44	06OCT2020	27OCT2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1083 10831029 (USA/50/M)	Placebo	Dose 1/96	07NOV2020		Neg/Neg/Unk	New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1085 10851286 (USA/52/F)	Placebo	Dose 1/24	02OCT2020	13OCT2020	Neg/Neg/Pos	Chills Sore throat	Pos/
C4591001 1085 10851293 (USA/63/F)*	Placebo	Dose 2/37	07NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1087 10871089 (USA/21/F)	Placebo	Dose 1/19	04SEP2020	30SEP2020	Neg/Neg/Unk	New or increased cough New loss of taste or smell Fever	Pos/
C4591001 1087 10871209 (USA/50/F)	BNT162b2 (30 µg)	Dose 1/7	31AUG2020	03SEP2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1088 10881219 (USA/63/M)*	Placebo	Dose 2/17	25OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1088 10881233 (USA/47/M)*	Placebo	Dose 2/15	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Fever	Pos/
C4591001 1089 10891217 (USA/64/F)	BNT162b2 (30 µg)	Dose 1/5	04SEP2020	12SEP2020	Neg/Neg/Pos	New or increased cough Chills Sore throat	Pos/
C4591001 1089 10891235 (USA/29/F)*	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	New or increased shortness of breath New or increased cough Sore throat	Pos/
C4591001 1090 10901121 (USA/58/F)*	Placebo	Dose 2/49	18OCT2020	22OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1090 10901353 (USA/63/M)*	Placebo	Dose 2/40	08NOV2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
						New or increased cough	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1091 10911014 (USA/52/M)	Placebo	Dose 2/76	03NOV2020		Neg/Neg/Neg	Fever Chills Diarrhea	Pos/
C4591001 1091 10911203 (USA/43/M)*	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Unk/Pos
C4591001 1091 10911387 (USA/17/F)	BNT162b2 (30 µg)	Dose 1/2	06NOV2020		Unk/Neg/Unk	Fever New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1092 10921021 (USA/60/F)*	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1092 10921130 (USA/53/M)*	Placebo	Dose 2/18	09OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1092 10921158 (USA/23/M)	Placebo	Dose 1/10	12SEP2020	21SEP2020	Neg/Neg/Pos	New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea	Pos/
C4591001 1092 10921268 (USA/64/F)	BNT162b2 (30 µg)	Dose 1/2	23OCT2020	28OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1093 10931014 (USA/68/M)	Placebo	Dose 2/1	08SEP2020	16SEP2020	Neg/Neg/Neg	New or increased muscle pain New or increased shortness of breath Chills	Pos/
C4591001 1093 10931050 (USA/62/M)	Placebo	Dose 1/24	16SEP2020	10NOV2020	Neg/Neg/Unk	New or increased muscle pain New or increased cough New loss of taste or smell	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1093 10931081 (USA/67/F)*	Placebo	Dose 2/19	05OCT2020	19OCT2020	Neg/Neg/Neg	Sore throat	Pos/
C4591001 1093 10931148 (USA/21/F)	Placebo	Dose 2/1	12OCT2020		Neg/Neg/Pos	New loss of taste or smell Diarrhea	Pos/
C4591001 1095 10951238 (USA/63/F)*	Placebo	Dose 2/19	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1095 10951260 (USA/25/M)*	Placebo	Dose 2/9	05NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1096 10961172 (USA/51/M)*	Placebo	Dose 2/49	06NOV2020	08NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1096 10961258 (USA/55/F)*	Placebo	Dose 2/25	22OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/Pos
C4591001 1096 10961388 (USA/17/F)	Placebo	Dose 1/4	12OCT2020	15OCT2020	Neg/Neg/Pos	Sore throat	Pos/
C4591001 1097 10971103 (USA/72/F)	Placebo	Dose 1/18	25SEP2020	03OCT2020	Neg/Neg/Pos	Fever New or increased cough New or increased muscle pain New loss of taste or smell Diarrhea	Pos/
C4591001 1097 10971104 (USA/73/M)	BNT162b2 (30 µg)	Dose 1/18	25SEP2020	06OCT2020	Neg/Neg/Pos	Fever New or increased cough New loss of taste or smell	Pos/
C4591001 1098 10981029 (USA/36/M)	BNT162b2 (30 µg)	Dose 1/11	31AUG2020	01SEP2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1098 10981062 (USA/63/F)*	Placebo	Dose 2/32	17OCT2020	20OCT2020	Neg/Neg/Neg	New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1101 11011024 (USA/54/F)	Placebo	Dose 1/11	19SEP2020	07OCT2020	Neg/Neg/Unk	Fever	Pos/
						New or increased cough	
						New or increased muscle pain	
C4591001 1101 11011095 (USA/60/M)*	Placebo	Dose 2/20	02NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1107 11071171 (USA/39/M)*	Placebo	Dose 2/58	10NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1109 11091067 (USA/42/M)*	Placebo	Dose 2/84	11NOV2020		Neg/Neg/Neg	Chills New or increased shortness of breath	Pos/
C4591001 1109 11091092 (USA/18/M)*	Placebo	Dose 2/70	31OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/
						New or increased cough	
						Sore throat	
C4591001 1109 11091323 (USA/64/M)*	Placebo	Dose 2/47	31OCT2020	02NOV2020	Neg/Neg/Neg	Fever	Pos/
						New or increased cough	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1109 11091416 (USA/46/F)*	Placebo	Dose 2/41	03NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Fever	Pos/
C4591001 1109 11091448 (USA/46/F)*	Placebo	Dose 2/9	06OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/ (R1 Pos)
C4591001 1109 11091482 (USA/63/M)*	Placebo	Dose 2/28	29OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/
C4591001 1109 11091556 (USA/41/M)	Placebo	Dose 1/8	11OCT2020	16OCT2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1110 11101006 (USA/34/F)	BNT162b2 (30 µg)	Dose 1/2	01AUG2020	16AUG2020	Neg/Neg/Pos	New or increased cough Chills	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1110 11101050 (USA/47/M)*	BNT162b2 (30 µg)	Dose 2/76	10NOV2020		Neg/Neg/Neg	New loss of taste or smell Vomiting New or increased cough	Pos/
C4591001 1110 11101072 (USA/42/M)	Placebo	Dose 2/4	28SEP2020		Neg/Neg/Pos	Chills Sore throat New loss of taste or smell Sore throat Diarrhea	Pos/
C4591001 1110 11101136 (USA/62/M)*	Placebo	Dose 2/52	04NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1110 11101162 (USA/51/M)*	BNT162b2 (30 µg)	Dose 2/34	24OCT2020		Neg/Neg/Neg	Chills Diarrhea New or increased cough	Pos/
C4591001 1111 11111010 (USA/75/M)*	Placebo	Dose 2/45	04OCT2020	05OCT2020	Neg/Neg/Neg	New loss of taste or smell Fever Chills	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1116 11161075 (USA/73/M)*	Placebo	Dose 2/43	03NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/
C4591001 1116 11161253 (USA/61/M)	Placebo	Dose 1/8	25SEP2020	06OCT2020	Neg/Neg/Pos	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1116 11161322 (USA/23/M)	Placebo	Dose 2/7	20OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1117 11171010 (USA/72/F)*	Placebo	Dose 2/34	11OCT2020	19OCT2020	Neg/Neg/Neg	Fever New or increased cough	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1118 11181088 (USA/73/M)*	Placebo	Dose 2/36	20OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1120 11201115 (USA/19/F)*	Placebo	Dose 2/73	06NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1120 11201335 (USA/63/F)	Placebo	Dose 1/8	23OCT2020		Neg/Neg/Unk	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea	Pos/
C4591001 1121 11211105 (USA/52/M)	Placebo	Dose 2/39	05NOV2020		Neg/Unk/Neg	Fever New or increased cough Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1122 11221025 (USA/40/M)*	Placebo	Dose 2/32	01NOV2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1123 11231025 (USA/60/F)	Placebo	Dose 2/77	08NOV2020		Neg/Neg/Unk	New or increased cough Sore throat	Pos/
C4591001 1123 11231073 (USA/25/F)*	Placebo	Dose 2/10	10SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/Pos
C4591001 1123 11231085 (USA/20/M)	Placebo	Dose 1/4	16AUG2020	27AUG2020	Neg/Neg/Pos	New or increased muscle pain	Pos/
C4591001 1123 11231086 (USA/35/F)*	Placebo	Dose 2/57	27OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1123 11231117 (USA/55/F)*	Placebo	Dose 2/64	10NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231144 (USA/53/F)	BNT162b2 (30 µg)	Dose 1/9	28AUG2020	19SEP2020	Neg/Unk/Unk	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/
C4591001 1123 11231214 (USA/60/F)*	Placebo	Dose 2/34	26OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat	Pos/
C4591001 1123 11231234 (USA/29/M)	Placebo	Dose 2/32	02NOV2020		Unk/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1123 11231255 (USA/76/M)*	Placebo	Dose 2/20	24OCT2020		Neg/Neg/Neg	New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231256 (USA/72/F)*	Placebo	Dose 2/24	28OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1123 11231284 (USA/67/M)*	Placebo	Dose 2/12	24OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1123 11231313 (USA/42/F)	Placebo	Dose 1/13	06OCT2020		Neg/Neg/Pos	Fever Chills New or increased muscle pain	Pos/
C4591001 1123 11231386 (USA/33/F)	BNT162b2 (30 µg)	Dose 1/8	26OCT2020	03NOV2020	Neg/Neg/Pos	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251006 (USA/35/M)*	Placebo	Dose 2/42	11OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills	Pos/
C4591001 1125 11251014 (USA/45/F)*	Placebo	Dose 2/59	30OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea	Pos/
C4591001 1125 11251023 (USA/49/M)*	Placebo	Dose 2/56	27OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain	Pos/
C4591001 1125 11251028 (USA/39/F)*	Placebo	Dose 2/27	29SEP2020	02OCT2020	Neg/Neg/Neg	Fever Chills	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251049 (USA/52/M)*	Placebo	Dose 2/50	27OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat New loss of taste or smell	Pos/
C4591001 1125 11251107 (USA/69/M)	Placebo	Dose 2/3	22OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1125 11251109 (USA/46/F)*	Placebo	Dose 2/51	04NOV2020		Neg/Neg/Neg	Chills Fever	Pos/
C4591001 1125 11251114 (USA/59/M)*	Placebo	Dose 2/38	22OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain Diarrhea Fever	Pos/Pos
C4591001 1125 11251124 (USA/39/M)*	Placebo	Dose 2/53	08NOV2020	10NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251148 (USA/54/F)	BNT162b2 (30 µg)	Dose 1/13	14SEP2020	23SEP2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1125 11251215 (USA/43/M)*	Placebo	Dose 2/25	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1125 11251222 (USA/85/F)	BNT162b2 (30 µg)	Dose 1/6	02NOV2020		Neg/Neg/Unk	New or increased cough	Pos/
C4591001 1125 11251238 (USA/17/F)	Placebo	Dose 1/12	02NOV2020		Neg/Neg/Unk	New loss of taste or smell	Pos/
C4591001 1126 11261017 (USA/34/F)*	Placebo	Dose 2/50	20OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1127 11271099 (USA/23/F)	Placebo	Dose 1/21	08SEP2020	16SEP2020	Neg/Neg/Pos	New or increased muscle pain New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat	Pos/
C4591001 1128 11281165 (USA/26/F)*	Placebo	Dose 2/46	29OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1131 11311100 (USA/64/M)*	Placebo	Dose 2/58	12NOV2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1131 11311138 (USA/45/F)*	Placebo	Dose 2/45	07NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1133 11331209 (USA/30/M)*	Placebo	Dose 2/32	10OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased cough	Pos/
C4591001 1133 11331512 (USA/36/M)	Placebo	Dose 1/17	11OCT2020		Neg/Neg/Unk	Sore throat Fever	Pos/
C4591001 1134 11341022 (USA/66/M)*	Placebo	Dose 2/29	29SEP2020	03OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased muscle pain	Pos/
C4591001 1135 11351148 (USA/35/M)	Placebo	Dose 2/3	10SEP2020	20SEP2020	Neg/Neg/Neg	Sore throat Fever New or increased cough New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1135 11351207 (USA/33/F)*	Placebo	Dose 2/30	13OCT2020		Neg/Neg/Neg	Sore throat New or increased muscle pain New loss of taste or smell Diarrhea	Pos/
C4591001 1141 11411020 (USA/29/M)	Placebo	Dose 2/6	29AUG2020	04SEP2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1141 11411088 (USA/52/M)*	Placebo	Dose 2/29	07OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1141 11411161 (USA/25/F)*	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	Chills Sore throat Fever New or increased cough New or increased muscle pain Diarrhea Vomiting	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1141 11411162 (USA/20/M)*	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1147 11471004 (USA/62/M)	Placebo	Dose 1/22	24AUG2020	28AUG2020	Neg/Neg/Unk	New or increased cough Sore throat	Pos/
C4591001 1147 11471035 (USA/52/M)	Placebo	Dose 1/18	23AUG2020	11SEP2020	Neg/Neg/Unk	New or increased cough Chills Sore throat	Pos/Pos
C4591001 1149 11491066 (USA/40/M)	Placebo	Dose 1/13	24AUG2020	04SEP2020	Neg/Neg/Neg	Fever New or increased cough	Pos/
C4591001 1149 11491113 (USA/69/M)*	BNT162b2 (30 µg)	Dose 2/44	23OCT2020	24OCT2020	Neg/Neg/Neg	Fever Chills Vomiting	Pos/
C4591001 1152 11521363 (USA/19/M)*	Placebo	Dose 2/9	06OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1152 11521372 (USA/28/F)*	Placebo	Dose 2/32	29OCT2020		Neg/Neg/Neg	New or increased cough Chills	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1156 11561006 (USA/45/M)	BNT162b2 (30 µg)	Dose 1/11	30AUG2020	01SEP2020	Neg/Pos/Neg	New or increased muscle pain Sore throat	Pos/Pos
C4591001 1156 11561033 (USA/55/F)	Placebo	Dose 1/11	05SEP2020	26SEP2020	Neg/Neg/Pos	New or increased cough	Pos/
C4591001 1156 11561044 (USA/63/M)	Placebo	Dose 1/6	01SEP2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1156 11561064 (USA/23/F)	BNT162b2 (30 µg)	Dose 1/7	04SEP2020	18SEP2020	Neg/Neg/Pos	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
						Chills New or increased muscle pain	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1162 11621044 (USA/22/M)	BNT162b2 (30 µg)	Dose 1/5	10AUG2020		Neg/Unk/Pos	New loss of taste or smell Diarrhea Fever	Pos/
C4591001 1162 11621075 (USA/40/F)*	Placebo	Dose 2/67	06NOV2020		Neg/Neg/Neg	Chills New loss of taste or smell Sore throat New or increased muscle pain	Pos/
C4591001 1163 11631113 (USA/25/M)*	Placebo	Dose 2/43	14OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1163 11631135 (USA/42/M)*	Placebo	Dose 2/21	30SEP2020	02OCT2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/
C4591001 1167 11671152 (USA/41/F)*	Placebo	Dose 2/26	20OCT2020		Neg/Neg/Neg	New or increased muscle pain Diarrhea Fever	Pos/Pos

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1167 11671157 (USA/58/M)*	Placebo	Dose 2/16	14OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/
C4591001 1168 11681004 (USA/54/M)*	Placebo	Dose 2/67	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
C4591001 1168 11681007 (USA/33/F)*	Placebo	Dose 2/36	06OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681008 (USA/37/M)*	Placebo	Dose 2/35	05OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat New or increased cough	Pos/
C4591001 1168 11681114 (USA/46/F)*	Placebo	Dose 2/23	13OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1168 11681117 (USA/37/M)*	Placebo	Dose 2/45	04NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1169 11691007 (USA/28/F)	Placebo	Dose 2/19	11OCT2020		Neg/Unk/Neg	New or increased muscle pain New or increased shortness of breath	Pos/
C4591001 1169 11691058 (USA/32/M)	Placebo	Dose 1/16	01OCT2020	11OCT2020	Neg/Neg/Pos	New loss of taste or smell Fever	Pos/
C4591001 1170 11701089 (USA/25/F)*	Placebo	Dose 2/16	01OCT2020		Neg/Neg/Neg	New or increased cough Chills Fever	Pos/
C4591001 1171 11711269 (USA/61/M)	Placebo	Dose 2/5	11OCT2020		Neg/Neg/Neg	Sore throat New or increased cough Chills	Pos/
C4591001 1174 11741053 (USA/24/F)	Placebo	Dose 2/5	05OCT2020		Neg/Neg/Neg	New loss of taste or smell Chills	Pos/
C4591001 1178 11781065 (USA/48/M)*	Placebo	Dose 2/23	13OCT2020	25OCT2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1178 11781238 (USA/60/F)*	Placebo	Dose 2/16	29OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/
						New or increased cough Chills New or increased muscle pain	
C4591001 1178 11781276 (USA/72/M)	BNT162b2 (30 µg)	Dose 2/7	27OCT2020		Neg/Neg/Unk	Sore throat New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1178 11781280 (USA/58/M)*	Placebo	Dose 2/9	03NOV2020		Neg/Neg/Neg	Sore throat Fever	Pos/
						New or increased cough Chills New or increased muscle pain	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1179 11791085 (USA/34/M)*	Placebo	Dose 2/34	09NOV2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1179 11791138 (USA/36/M)	BNT162b2 (30 µg)	Dose 1/8	31OCT2020		Neg/Neg/Unk	New or increased cough New or increased muscle pain Fever	Pos/
C4591001 1194 11941061 (DEU/51/M)	BNT162b2 (30 µg)	Dose 1/6	24OCT2020		Neg/Pos/Unk	New or increased cough New or increased muscle pain Sore throat New loss of taste or smell	Pos/Pos
C4591001 1203 12031037 (DEU/36/M)	BNT162b2 (30 µg)	Dose 1/6	26OCT2020	30OCT2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1207 12071024 (TUR/43/M)	BNT162b2 (30 µg)	Dose 1/8	04NOV2020		Unk/Neg/Unk	New or increased cough Chills	Pos/
C4591001 1209 12091013 (TUR/32/M)	BNT162b2 (30 µg)	Dose 1/6	07NOV2020	09NOV2020	Neg/Pos/Unk	New loss of taste or smell New loss of taste or smell	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1221 12211002 (USA/43/M)	Placebo	Dose 1/20	01NOV2020		Neg/Neg/Unk	Vomiting Chills	Unk/Pos
C4591001 1223 12231005 (USA/20/F)*	Placebo	Dose 2/51	06NOV2020		Neg/Neg/Neg	Vomiting New or increased cough Chills	Pos/
C4591001 1223 12231096 (USA/77/F)*	Placebo	Dose 2/48	11NOV2020	12NOV2020	Neg/Neg/Neg	Sore throat New or increased cough Chills	Pos/
C4591001 1226 12261309 (BRA/61/M)*	Placebo	Dose 2/40	20OCT2020	26OCT2020	Neg/Neg/Neg	New or increased cough Chills	Pos/
C4591001 1226 12261360 (BRA/26/M)	Placebo	Dose 2/1	11SEP2020		Neg/Neg/Pos	New or increased cough New loss of taste or smell	Pos/
C4591001 1226 12261363 (BRA/48/F)*	Placebo	Dose 2/23	03OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261599 (BRA/41/F)*	BNT162b2 (30 µg)	Dose 2/36	06NOV2020		Neg/Neg/Neg	Sore throat Vomiting New or increased cough	Pos/
C4591001 1226 12261624 (BRA/52/M)*	Placebo	Dose 2/34	02NOV2020		Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/
C4591001 1226 12261660 (BRA/27/F)*	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1226 12261894 (BRA/28/M)	Placebo	Dose 1/5	29SEP2020	02OCT2020	Neg/Neg/Pos	New or increased muscle pain Fever Chills New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261964 (BRA/27/F)*	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1226 12262111 (BRA/51/M)*	Placebo	Dose 2/12	10NOV2020	12NOV2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1226 12262189 (BRA/22/M)	Placebo	Dose 1/14	27OCT2020	01NOV2020	Neg/Neg/Unk	New or increased cough	Pos/
C4591001 1226 12262267 (BRA/27/F)	Placebo	Dose 1/2	18OCT2020		Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12311043 (ARG/46/M)*	Placebo	Dose 2/40	10OCT2020	11OCT2020	Neg/Neg/Neg	New or increased cough Chills	Pos/
C4591001 1231 12311054 (ARG/37/M)	Placebo	Dose 1/8	18AUG2020	18AUG2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1231 12311087 (ARG/44/M)	Placebo	Dose 1/15	26AUG2020	15SEP2020	Neg/Neg/Pos	Fever New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311147 (ARG/31/M)	Placebo	Dose 1/5	17AUG2020	30AUG2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea Vomiting	Pos/
C4591001 1231 12311195 (ARG/53/M)	Placebo	Dose 1/16	29AUG2020	10OCT2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 1231 12311267 (ARG/67/M)*	Placebo	Dose 2/24	26SEP2020	07OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12311356 (ARG/30/F)	Placebo	Dose 1/17	31AUG2020	18SEP2020	Neg/Neg/Unk	New or increased cough Sore throat New or increased muscle pain	Pos/
C4591001 1231 12311391 (ARG/28/F)	Placebo	Dose 1/10	24AUG2020		Neg/Neg/Unk	New loss of taste or smell New or increased cough New or increased muscle pain Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311407 (ARG/63/M)*	Placebo	Dose 2/24	27SEP2020	06OCT2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Diarrhea	Pos/
C4591001 1231 12311431 (ARG/21/M)	Placebo	Dose 1/3	17AUG2020	07SEP2020	Neg/Neg/Unk	Fever New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1231 12311531 (ARG/35/M)*	Placebo	Dose 2/9	16SEP2020	27SEP2020	Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1231 12311532 (ARG/50/M) µg)	BNT162b2 (30	Dose 1/8	23AUG2020	25AUG2020	Neg/Neg/Pos	Fever New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311549 (ARG/58/F)	Placebo	Dose 1/13	28AUG2020	13SEP2020	Neg/Neg/Pos	Fever	Pos/
C4591001 1231 12311556 (ARG/24/M)*	Placebo	Dose 2/45	21OCT2020	09NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12311560 (ARG/44/M)*	Placebo	Dose 2/70	12NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12311568 (ARG/43/M)	Placebo	Dose 1/6	21AUG2020	10SEP2020	Neg/Neg/Pos	New or increased cough	Pos/
C4591001 1231 12311641 (ARG/25/M)	BNT162b2 (30 µg)	Dose 1/10	25AUG2020	15SEP2020	Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12311651 (ARG/52/F)*	Placebo	Dose 2/8	14SEP2020	01OCT2020	Neg/Neg/Neg	New or increased cough	Pos/
						Chills	
						New or increased muscle pain	
						Sore throat	
						Vomiting	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311656 (ARG/20/F)	Placebo	Dose 1/24	08SEP2020	20SEP2020	Neg/Neg/Pos	New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1231 12311664 (ARG/34/F)*	Placebo	Dose 2/9	15SEP2020	03OCT2020	Neg/Neg/Neg	Fever New or increased cough	Pos/
C4591001 1231 12311754 (ARG/54/M)*	Placebo	Dose 2/38	14OCT2020	25OCT2020	Neg/Neg/Neg	Fever New or increased muscle pain Sore throat	Pos/
C4591001 1231 12311764 (ARG/34/M)*	Placebo	Dose 2/63	09NOV2020	09NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12311911 (ARG/41/F)	BNT162b2 (30 µg)	Dose 1/8	25AUG2020	30AUG2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/
C4591001 1231 12311982 (ARG/41/F)*	Placebo	Dose 2/37	14OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312130 (ARG/64/F)	Placebo	Dose 1/3	20AUG2020	27AUG2020	Neg/Pos/Neg	Sore throat Fever	Pos/
C4591001 1231 12312320 (ARG/51/F)	Placebo	Dose 1/61	18OCT2020		Neg/Neg/Unk	New or increased cough Sore throat	Pos/
C4591001 1231 12312334 (ARG/40/F)	Placebo	Dose 1/15	02SEP2020		Neg/Neg/Pos	New loss of taste or smell	Pos/
C4591001 1231 12312339 (ARG/22/F)	BNT162b2 (30 µg)	Dose 1/6	24AUG2020	23SEP2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12312375 (ARG/43/F)	BNT162b2 (30 µg)	Dose 1/9	27AUG2020	07SEP2020	Neg/Neg/Pos	New loss of taste or smell	Pos/
C4591001 1231 12312479 (ARG/43/M)*	Placebo	Dose 2/30	09OCT2020		Neg/Neg/Neg	Sore throat Vomiting New or increased cough	Pos/
						Chills New or increased muscle pain New loss of taste or smell	

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312507 (ARG/47/F)*	Placebo	Dose 2/10	17SEP2020	28SEP2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312571 (ARG/62/M)	Placebo	Dose 1/13	01SEP2020	13SEP2020	Neg/Neg/Pos	Fever New or increased cough	Pos/
C4591001 1231 12312630 (ARG/39/F)*	Placebo	Dose 2/44	23OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312635 (ARG/71/M)*	Placebo	Dose 2/27	04OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills Sore throat	Pos/
C4591001 1231 12312660 (ARG/35/M)	Placebo	Dose 1/23	11SEP2020	23SEP2020	Neg/Neg/Neg	New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312679 (ARG/32/M)	Placebo	Dose 2/4	14SEP2020	14NOV2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1231 12312752 (ARG/36/M)	Placebo	Dose 1/17	06SEP2020	24SEP2020	Neg/Neg/Pos	New or increased cough Diarrhea Fever	Pos/
C4591001 1231 12312763 (ARG/43/F)	Placebo	Dose 1/19	08SEP2020		Neg/Neg/Pos	New or increased cough New or increased cough	Pos/
C4591001 1231 12312805 (ARG/33/M)	BNT162b2 (30 µg)	Dose 1/17	06SEP2020	08SEP2020	Neg/Pos/Neg	New loss of taste or smell New or increased cough	Pos/
C4591001 1231 12312867 (ARG/40/F)*	Placebo	Dose 2/35	14OCT2020	01NOV2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12312914 (ARG/50/M)*	Placebo	Dose 2/43	26OCT2020		Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313006 (ARG/50/F)	BNT162b2 (30 µg)	Dose 1/2	22AUG2020	30AUG2020	Neg/Pos/Pos	New or increased cough New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12313068 (ARG/41/M)	Placebo	Dose 1/5	26AUG2020	31AUG2020	Neg/Neg/Pos	Chills Sore throat New or increased muscle pain	Pos/
C4591001 1231 12313069 (ARG/36/M)	Placebo	Dose 1/9	30AUG2020	19SEP2020	Neg/Neg/Pos	New loss of taste or smell New or increased cough New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12313090 (ARG/57/M)	Placebo	Dose 1/13	03SEP2020	28SEP2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1231 12313103 (ARG/73/M)	Placebo	Dose 1/10	31AUG2020	10SEP2020	Neg/Neg/Pos	New or increased shortness of breath Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313125 (ARG/48/M)	Placebo	Dose 1/76	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Diarrhea Fever	Pos/
C4591001 1231 12313182 (ARG/33/M)*	Placebo	Dose 2/10	20SEP2020	19OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased shortness of breath	Pos/
C4591001 1231 12313225 (ARG/55/F)	BNT162b2 (30 µg)	Dose 1/3	24AUG2020	24AUG2020	Neg/Pos/Pos	New loss of taste or smell New loss of taste or smell	Pos/
C4591001 1231 12313296 (ARG/49/F)*	Placebo	Dose 2/25	04OCT2020	20OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1231 12313357 (ARG/31/M)	BNT162b2 (30 µg)	Dose 1/3	25AUG2020	30AUG2020	Neg/Neg/Pos	New loss of taste or smell Fever	Pos/

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313395 (ARG/39/M)	Placebo	Dose 1/2	24AUG2020	31AUG2020	Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12313400 (ARG/46/M)*	Placebo	Dose 2/37	19OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/
C4591001 1231 12313422 (ARG/34/M)*	Placebo	Dose 2/44	28OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Diarrhea	Pos/
C4591001 1231 12313457 (ARG/60/M)	Placebo	Dose 1/5	27AUG2020	18SEP2020	Unk/Neg/Pos	Fever New or increased cough New or increased muscle pain	Pos/
C4591001 1231 12313510 (ARG/29/F)	Placebo	Dose 1/13	04SEP2020	07SEP2020	Unk/Neg/Pos	Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313520 (ARG/28/F)*	Placebo	Dose 2/8	22SEP2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased cough	Pos/
C4591001 1231 12313657 (ARG/48/F)	Placebo	Dose 1/11	03SEP2020	18SEP2020	Neg/Neg/Pos	New loss of taste or smell Sore throat Chills	Pos/
C4591001 1231 12313662 (ARG/27/M)	BNT162b2 (30 µg)	Dose 1/8	31AUG2020	10SEP2020	Neg/Neg/Neg	New or increased muscle pain Sore throat New or increased cough	Pos/
C4591001 1231 12313668 (ARG/33/M)*	Placebo	Dose 2/12	24SEP2020	02OCT2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea New loss of taste or smell	Pos/
C4591001 1231 12313709 (ARG/38/M)	BNT162b2 (30 µg)	Dose 1/14	06SEP2020	03OCT2020	Neg/Neg/Neg	Sore throat New loss of taste or smell Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313787 (ARG/58/M)*	Placebo	Dose 2/48	02NOV2020	05NOV2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1231 12313895 (ARG/50/F)*	Placebo	Dose 2/21	03OCT2020	17OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12314112 (ARG/52/M)*	Placebo	Dose 2/42	28OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1231 12314301 (ARG/56/M)	BNT162b2 (30 µg)	Dose 1/4	29AUG2020	30SEP2020	Neg/Neg/Pos	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12314308 (ARG/31/F)*	Placebo	Dose 2/15	30SEP2020	11OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Vomiting	Pos/
C4591001 1231 12314314 (ARG/33/F)	BNT162b2 (30 µg)	Dose 1/2	27AUG2020	29AUG2020	Neg/Pos/Unk	Fever	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314477 (ARG/36/M)	Placebo	Dose 2/16	03OCT2020	15OCT2020	Pos/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1231 12314492 (ARG/23/F)	Placebo	Dose 1/2	28AUG2020	09SEP2020	Neg/Pos/Pos	Fever New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12314534 (ARG/18/F)*	Placebo	Dose 2/21	05OCT2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12314622 (ARG/32/F)*	Placebo	Dose 2/15	01OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314700 (ARG/43/M)	BNT162b2 (30 µg)	Dose 1/7	03SEP2020	04OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Fever	Pos/
C4591001 1231 12315636 (ARG/53/F)*	Placebo	Dose 2/35	23OCT2020		Neg/Neg/Neg	New or increased cough Sore throat New or increased cough	Pos/
C4591001 1231 12315637 (ARG/40/F)*	Placebo	Dose 2/11	29SEP2020	08OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1235 12351027 (USA/50/M)	Placebo	Dose 1/18	23SEP2020	03OCT2020	Neg/Neg/Unk	Chills New or increased muscle pain New loss of taste or smell Fever New or increased cough	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1235 12351071 (USA/50/M)	Placebo	Dose 1/8	21SEP2020	25SEP2020	Neg/Neg/Unk	New or increased shortness of breath Chills Vomiting Fever	Pos/
C4591001 1235 12351093 (USA/30/F)*	BNT162b2 (30 µg)	Dose 2/32	08NOV2020	14NOV2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/ or smell
C4591001 1235 12351187 (USA/23/F)	Placebo	Dose 1/8	23OCT2020		Neg/Neg/Unk	Fever	Pos/
C4591001 1235 12351188 (USA/36/F)	BNT162b2 (30 µg)	Dose 1/6	21OCT2020		Neg/Neg/Unk	New or increased cough Sore throat Chills	Pos/
C4591001 1241 12411260 (BRA/39/M)	Placebo	Dose 1/12	30AUG2020	13SEP2020	Neg/Neg/Unk	New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1241 12411688 (BRA/29/M)	Placebo	Dose 1/13	27SEP2020	15OCT2020	Neg/Neg/Pos	New loss of taste or smell New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/Pos
C4591001 1241 12411695 (BRA/44/F)	Placebo	Dose 1/4	18SEP2020	05OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1241 12411885 (BRA/23/M)	BNT162b2 (30 µg)	Dose 2/14	22OCT2020	24OCT2020	Pos/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/Neg
C4591001 1241 12412017 (BRA/59/M)*	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	Fever New or increased muscle pain	Pos/Pos

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1241 12412018 (BRA/55/F)*	Placebo	Dose 2/8	28OCT2020		Neg/Neg/Neg	Fever	Pos/Pos
C4591001 1241 12412215 (BRA/39/M)	Placebo	Dose 2/3	06NOV2020		Neg/Neg/Pos	Sore throat Fever	Pos/
C4591001 1241 12412355 (BRA/38/F)	Placebo	Dose 1/3	21OCT2020	04NOV2020	Neg/Neg/Pos	Chills New or increased muscle pain New loss of taste or smell New loss of taste or smell	Pos/
C4591001 1241 12412568 (BRA/60/F)	Placebo	Dose 1/7	10NOV2020		Unk/Neg/Unk	Diarrhea Fever	Unk/Pos
C4591001 1247 12471066 (ZAF/58/F)	Placebo	Dose 1/17	15OCT2020		Neg/Neg/Unk	New or increased cough Vomiting	Pos/
C4591001 1247 12471085 (ZAF/54/F)	Placebo	Dose 2/12	30OCT2020	03NOV2020	Neg/Unk/Neg	New or increased shortness of breath New or increased cough Chills	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1251 12511159 (USA/37/F)*	Placebo	Dose 2/26	26OCT2020	29OCT2020	Neg/Neg/Neg	Diarrhea New or increased cough New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1251 12511207 (USA/48/M)	Placebo	Dose 1/3	25SEP2020	29SEP2020	Neg/Neg/Pos	New or increased cough	Pos/
C4591001 1251 12511209 (USA/62/M)	Placebo	Dose 2/7	19OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 4444 44441025 (ARG/51/M)	Placebo	Dose 1/8	28SEP2020	05OCT2020	Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell	Pos/
C4591001 4444 44441044 (ARG/35/F)	Placebo	Dose 1/13	03OCT2020	10OCT2020	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/
C4591001 4444 44441092 (ARG/64/M)*	Placebo	Dose 2/23	03NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441144 (ARG/38/M)*	Placebo	Dose 2/26	07NOV2020		Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 4444 44441204 (ARG/59/F)*	BNT162b2 (30 µg)	Dose 2/21	02NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea	Pos/ muscle pain
C4591001 4444 44441224 (ARG/52/M)*	Placebo	Dose 2/13	25OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 4444 44441253 (ARG/49/M)	Placebo	Dose 1/5	25SEP2020	09OCT2020	Pos/Neg/Neg	New or increased shortness of breath New or increased muscle pain New or increased cough Sore throat	Pos/

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.1 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441560 (ARG/38/F)	Placebo	Dose 1/7	29SEP2020	07OCT2020	Neg/Neg/Pos	New or increased muscle pain Sore throat	Pos/
C4591001 4444 44441563 (ARG/38/M)*	Placebo	Dose 2/8	21OCT2020		Neg/Neg/Neg	New loss of taste or smell Diarrhea	Pos/
C4591001 4444 44441787 (ARG/62/M)	Placebo	Dose 1/4	26SEP2020	27SEP2020	Pos/Neg/Neg	New or increased cough	Pos/
C4591001 4444 44442188 (ARG/24/M)	BNT162b2 (30 µg)	Dose 1/9	05OCT2020		Neg/Pos/Pos	New or increased cough	Pos/
C4591001 4444 44442304 (ARG/49/M)	Placebo	Dose 2/12	26OCT2020	11NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/

Abbreviations: ARG = Argentina; BRA = Brazil; DEU = Germany; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown; ZAF = South Africa.

Note: * indicates subject in the evaluable efficacy (7 days) population with first COVID-19 occurrence from 7 days after Dose 2 and without evidence of infection prior to 7 days after Dose 2.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

Note: † = HIV-positive subject.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (16:08) Source Data: adsympt Table Generation: 18NOV2020 (08:45)

(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_Efficacy_FA_164/adsympt_1001_sympt_d1_aai

090177e1959af312\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1003 10031122 (USA/48/M)	Placebo	Dose 2/77	05NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Chills	
C4591001 1006 10061012 (USA/53/M)	Placebo	Dose 2/68	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased shortness of breath	
						New or increased muscle pain	
C4591001 1006 10061066 (USA/39/F)	Placebo	Dose 2/59	11NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061084 (USA/27/F)	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
C4591001 1006 10061091 (USA/20/F)	Placebo	Dose 2/50	30OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061114 (USA/21/M)	Placebo	Dose 2/35	20OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased muscle pain	
						New loss of taste or smell	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081011 (USA/55/F)	Placebo	Dose 2/52	22OCT2020	31OCT2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 1008 10081048 (USA/38/F)	Placebo	Dose 2/60	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1008 10081130 (USA/52/F)	Placebo	Dose 2/32	17OCT2020	29OCT2020	Neg/Neg/Neg	Sore throat New or increased shortness of breath	Pos/
C4591001 1008 10081214 (USA/62/M)	Placebo	Dose 2/42	09NOV2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1008 10081319 (USA/79/F)	Placebo	Dose 2/31	04NOV2020		Neg/Neg/Neg	Chills	Pos/
C4591001 1008 10081356 (USA/63/M)	Placebo	Dose 2/25	31OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1009 10091128 (USA/51/M)	Placebo	Dose 2/30	15OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1013 10131288 (USA/53/M)	Placebo	Dose 2/11	25SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1013 10131475 (USA/49/F)	Placebo	Dose 2/23	22OCT2020	25OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1016 10161003 (USA/23/F)	Placebo	Dose 2/57	14OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161004 (USA/51/F)	BNT162b2 (30 µg)	Dose 2/58	15OCT2020	22OCT2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell New loss of taste or smell	Pos/
C4591001 1016 10161017 (USA/18/F)	Placebo	Dose 2/19	07SEP2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1016 10161035 (USA/70/F)	Placebo	Dose 2/67	29OCT2020	29OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1016 10161048 (USA/52/F)	Placebo	Dose 2/75	06NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1016 10161183 (USA/31/F)	Placebo	Dose 2/32	16OCT2020	01NOV2020	Neg/Neg/Neg	Fever	Pos/ (R1 Pos)
						New or increased cough	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161207 (USA/62/F)	Placebo	Dose 2/27	14OCT2020		Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/ cough
C4591001 1018 10181198 (USA/50/F)	Placebo	Dose 2/55	04NOV2020	05NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Fever	Pos/ cough
C4591001 1019 10191038 (USA/47/F)	Placebo	Dose 2/61	03NOV2020		Neg/Neg/Neg	New or increased cough Fever	Pos/ cough
C4591001 1019 10191184 (USA/52/M)	Placebo	Dose 2/36	05NOV2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased cough	Pos/ cough

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1028 10281038 (USA/53/F)	Placebo	Dose 2/31	10OCT2020	22OCT2020	Neg/Neg/Neg	New or increased muscle pain Vomiting Fever	Pos/
C4591001 1028 10281100 (USA/47/F)	Placebo	Dose 2/19	11OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1028 10281132 (USA/61/M)	Placebo	Dose 2/14	11OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1028 10281138 (USA/38/F)	Placebo	Dose 2/25	23OCT2020		Neg/Neg/Neg	Chills Sore throat Diarrhea	Pos/
C4591001 1037 10371036 (USA/62/M)	Placebo	Dose 2/52	31OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1037 10371280 (USA/58/M)	Placebo	Dose 2/28	10NOV2020		Neg/Neg/Neg	New or increased cough Chills Fever	Pos/
C4591001 1038 10381051 (USA/69/M)	Placebo	Dose 2/51	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1039 10391025 (USA/55/F)	Placebo	Dose 2/40	25OCT2020	03NOV2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 1046 10461058 (USA/44/F)	Placebo	Dose 2/62	09NOV2020		Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1047 10471024 (USA/63/F)	BNT162b2 (30 µg)	Dose 2/37	16OCT2020	18OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1068 10681082 (USA/58/M)	Placebo	Dose 2/42	01NOV2020		Neg/Neg/Neg	Diarrhea Vomiting Fever	Pos/
						New or increased cough	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1068 10681110 (USA/30/F)	Placebo	Dose 2/22	16OCT2020		Neg/Neg/Neg	New or increased shortness of breath Sore throat New or increased cough	Pos/
C4591001 1071 10711022 (USA/47/M)	Placebo	Dose 2/72	10NOV2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1071 10711058 (USA/72/F)	Placebo	Dose 2/60	06NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Sore throat New or increased cough	Pos/
C4591001 1072 10721057 (USA/70/M)	Placebo	Dose 2/41	26OCT2020		Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1077 10771195 (USA/73/F)	Placebo	Dose 2/40	01NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1079 10791046 (USA/55/F)	Placebo	Dose 2/62	26OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1079 10791054 (USA/28/F)	Placebo	Dose 2/63	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1081 10811151 (USA/79/F)	Placebo	Dose 2/10	30SEP2020	14OCT2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1082 10821016 (USA/46/F)	Placebo	Dose 2/44	06OCT2020	27OCT2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1085 10851293 (USA/63/F)	Placebo	Dose 2/37	07NOV2020		Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell	Pos/
C4591001 1088 10881219 (USA/63/M)	Placebo	Dose 2/17	25OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/
C4591001 1088 10881233 (USA/47/M)	Placebo	Dose 2/15	02NOV2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1089 10891235 (USA/29/F)	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	New or increased cough Chills Sore throat	Pos/
C4591001 1090 10901121 (USA/58/F)	Placebo	Dose 2/49	18OCT2020	22OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1090 10901353 (USA/63/M)	Placebo	Dose 2/40	08NOV2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1091 10911203 (USA/43/M)	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased cough	Unk/Pos
C4591001 1092 10921021 (USA/60/F)	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/
						New or increased cough Chills New or increased muscle pain	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1092 10921130 (USA/53/M)	Placebo	Dose 2/18	09OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea	Pos/
C4591001 1093 10931081 (USA/67/F)	Placebo	Dose 2/19	05OCT2020	19OCT2020	Neg/Neg/Neg	Sore throat	Pos/
C4591001 1095 10951238 (USA/63/F)	Placebo	Dose 2/19	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1095 10951260 (USA/25/M)	Placebo	Dose 2/9	05NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1096 10961172 (USA/51/M)	Placebo	Dose 2/49	06NOV2020	08NOV2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1096 10961258 (USA/55/F)	Placebo	Dose 2/25	22OCT2020		Neg/Neg/Neg	New or increased cough New or increased cough	Pos/Pos
C4591001 1098 10981062 (USA/63/F)	Placebo	Dose 2/32	17OCT2020	20OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/
C4591001 1101 11011095 (USA/60/M)	Placebo	Dose 2/20	02NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1107 11071171 (USA/39/M)	Placebo	Dose 2/58	10NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1109 11091067 (USA/42/M)	Placebo	Dose 2/84	11NOV2020		Neg/Neg/Neg	Chills New or increased shortness of breath	Pos/
C4591001 1109 11091092 (USA/18/M)	Placebo	Dose 2/70	31OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/
						New or increased cough Sore throat	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1109 11091323 (USA/64/M)	Placebo	Dose 2/47	31OCT2020	02NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1109 11091416 (USA/46/F)	Placebo	Dose 2/41	03NOV2020		Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/
C4591001 1109 11091448 (USA/46/F)	Placebo	Dose 2/9	06OCT2020	28OCT2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/ (R1 Pos)
C4591001 1109 11091482 (USA/63/M)	Placebo	Dose 2/28	29OCT2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1110 11101050 (USA/47/M)	BNT162b2 (30 µg)	Dose 2/76	10NOV2020		Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1110 11101136 (USA/62/M)	Placebo	Dose 2/52	04NOV2020		Neg/Neg/Neg	Chills Sore throat New or increased cough	Pos/
C4591001 1110 11101162 (USA/51/M)	BNT162b2 (30 µg)	Dose 2/34	24OCT2020		Neg/Neg/Neg	Chills Diarrhea New or increased cough	Pos/
C4591001 1111 11111010 (USA/75/M)	Placebo	Dose 2/45	04OCT2020	05OCT2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1116 11161075 (USA/73/M)	Placebo	Dose 2/43	03NOV2020		Neg/Neg/Neg	Chills New or increased cough New or increased shortness of breath	Pos/
C4591001 1117 11171010 (USA/72/F)	Placebo	Dose 2/34	11OCT2020	19OCT2020	Neg/Neg/Neg	Chills Fever	Pos/
C4591001 1118 11181088 (USA/73/M)	Placebo	Dose 2/36	20OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1120 11201115 (USA/19/F)	Placebo	Dose 2/73	06NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1122 11221025 (USA/40/M)	Placebo	Dose 2/32	01NOV2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1123 11231073 (USA/25/F)	Placebo	Dose 2/10	10SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/Pos
C4591001 1123 11231086 (USA/35/F)	Placebo	Dose 2/57	27OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1123 11231117 (USA/55/F)	Placebo	Dose 2/64	10NOV2020		Neg/Neg/Neg	Chills	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231214 (USA/60/F)	Placebo	Dose 2/34	26OCT2020		Neg/Neg/Neg	New or increased muscle pain New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat	Pos/
C4591001 1123 11231255 (USA/76/M)	Placebo	Dose 2/20	24OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1123 11231256 (USA/72/F)	Placebo	Dose 2/24	28OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1123 11231284 (USA/67/M)	Placebo	Dose 2/12	24OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1125 11251006 (USA/35/M)	Placebo	Dose 2/42	11OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
						New or increased cough Chills	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251014 (USA/45/F)	Placebo	Dose 2/59	30OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea	Pos/
C4591001 1125 11251023 (USA/49/M)	Placebo	Dose 2/56	27OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain	Pos/
C4591001 1125 11251028 (USA/39/F)	Placebo	Dose 2/27	29SEP2020	02OCT2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Sore throat	Pos/
C4591001 1125 11251049 (USA/52/M)	Placebo	Dose 2/50	27OCT2020		Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251109 (USA/46/F)	Placebo	Dose 2/51	04NOV2020		Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain Diarrhea	Pos/
C4591001 1125 11251114 (USA/59/M)	Placebo	Dose 2/38	22OCT2020		Neg/Neg/Neg	Fever	Pos/Pos
C4591001 1125 11251124 (USA/39/M)	Placebo	Dose 2/53	08NOV2020	10NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/
C4591001 1125 11251215 (USA/43/M)	Placebo	Dose 2/25	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1126 11261017 (USA/34/F)	Placebo	Dose 2/50	20OCT2020		Neg/Neg/Neg	Fever New or increased muscle pain	Pos/
C4591001 1128 11281165 (USA/26/F)	Placebo	Dose 2/46	29OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1131 11311100 (USA/64/M)	Placebo	Dose 2/58	12NOV2020		Neg/Neg/Neg	Fever Chills	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1131 11311138 (USA/45/F)	Placebo	Dose 2/45	07NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1133 11331209 (USA/30/M)	Placebo	Dose 2/32	10OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased cough	Pos/
C4591001 1134 11341022 (USA/66/M)	Placebo	Dose 2/29	29SEP2020	03OCT2020	Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1135 11351207 (USA/33/F)	Placebo	Dose 2/30	13OCT2020		Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1141 11411088 (USA/52/M)	Placebo	Dose 2/29	07OCT2020		Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever	Pos/
C4591001 1141 11411161 (USA/25/F)	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	Chills Sore throat Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1141 11411162 (USA/20/M)	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Diarrhea Vomiting	Pos/
C4591001 1149 11491113 (USA/69/M)	BNT162b2 (30 µg)	Dose 2/44	23OCT2020	24OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1152 11521363 (USA/19/M)	Placebo	Dose 2/9	06OCT2020		Neg/Neg/Neg	Chills Vomiting	Pos/
C4591001 1152 11521372 (USA/28/F)	Placebo	Dose 2/32	29OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1162 11621075 (USA/40/F)	Placebo	Dose 2/67	06NOV2020		Neg/Neg/Neg	New or increased muscle pain	Pos/
C4591001 1163 11631113 (USA/25/M)	Placebo	Dose 2/43	14OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1163 11631135 (USA/42/M)	Placebo	Dose 2/21	30SEP2020	02OCT2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/
C4591001 1167 11671152 (USA/41/F)	Placebo	Dose 2/26	20OCT2020		Neg/Neg/Neg	New or increased muscle pain Diarrhea Fever	Pos/Pos
C4591001 1167 11671157 (USA/58/M)	Placebo	Dose 2/16	14OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/
						New or increased cough Chills	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681004 (USA/54/M)	Placebo	Dose 2/67	07NOV2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/
C4591001 1168 11681007 (USA/33/F)	Placebo	Dose 2/36	06OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New or increased cough	Pos/
C4591001 1168 11681008 (USA/37/M)	Placebo	Dose 2/35	05OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat New or increased cough	Pos/
C4591001 1168 11681114 (USA/46/F)	Placebo	Dose 2/23	13OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever New or increased cough Chills	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681117 (USA/37/M)	Placebo	Dose 2/45	04NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/
C4591001 1170 11701089 (USA/25/F)	Placebo	Dose 2/16	01OCT2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/
C4591001 1178 11781065 (USA/48/M)	Placebo	Dose 2/23	13OCT2020	25OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1178 11781238 (USA/60/F)	Placebo	Dose 2/16	29OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/
						New or increased cough Chills	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1178 11781280 (USA/58/M)	Placebo	Dose 2/9	03NOV2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/
C4591001 1179 11791085 (USA/34/M)	Placebo	Dose 2/34	09NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1223 12231005 (USA/20/F)	Placebo	Dose 2/51	06NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New or increased cough Chills Sore throat	Pos/
C4591001 1223 12231096 (USA/77/F)	Placebo	Dose 2/48	11NOV2020	12NOV2020	Neg/Neg/Neg	New or increased cough Chills	Pos/
C4591001 1226 12261309 (BRA/61/M)	Placebo	Dose 2/40	20OCT2020	26OCT2020	Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261363 (BRA/48/F)	Placebo	Dose 2/23	03OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Vomiting	Pos/
C4591001 1226 12261599 (BRA/41/F)	BNT162b2 (30 µg)	Dose 2/36	06NOV2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/
C4591001 1226 12261624 (BRA/52/M)	Placebo	Dose 2/34	02NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1226 12261660 (BRA/27/F)	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain	Pos/
C4591001 1226 12261964 (BRA/27/F)	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
						Chills New or increased muscle pain New loss of taste or smell Sore throat	
C4591001 1226 12262111 (BRA/51/M)	Placebo	Dose 2/12	10NOV2020	12NOV2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12311043 (ARG/46/M)	Placebo	Dose 2/40	10OCT2020	11OCT2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1231 12311267 (ARG/67/M)	Placebo	Dose 2/24	26SEP2020	07OCT2020	Neg/Neg/Neg	Chills Fever	Pos/
C4591001 1231 12311407 (ARG/63/M)	Placebo	Dose 2/24	27SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/
C4591001 1231 12311531 (ARG/35/M)	Placebo	Dose 2/9	16SEP2020	27SEP2020	Neg/Neg/Neg	Chills New or increased muscle pain Diarrhea Fever	Pos/
						New or increased shortness of breath	

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311556 (ARG/24/M)	Placebo	Dose 2/45	21OCT2020	09NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12311560 (ARG/44/M)	Placebo	Dose 2/70	12NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12311651 (ARG/52/F)	Placebo	Dose 2/8	14SEP2020	01OCT2020	Neg/Neg/Neg	New or increased cough New or increased cough	Pos/
C4591001 1231 12311664 (ARG/34/F)	Placebo	Dose 2/9	15SEP2020	03OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Vomiting Fever	Pos/
C4591001 1231 12311754 (ARG/54/M)	Placebo	Dose 2/38	14OCT2020	25OCT2020	Neg/Neg/Neg	New or increased cough Fever	Pos/
C4591001 1231 12311764 (ARG/34/M)	Placebo	Dose 2/63	09NOV2020	09NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat New loss of taste or smell	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b)
C4591001 1231 12311982 (ARG/41/F)	Placebo	Dose 2/37	14OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312479 (ARG/43/M)	Placebo	Dose 2/30	09OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12312507 (ARG/47/F)	Placebo	Dose 2/10	17SEP2020	28SEP2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312630 (ARG/39/F)	Placebo	Dose 2/44	23OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312635 (ARG/71/M)	Placebo	Dose 2/27	04OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312867 (ARG/40/F)	Placebo	Dose 2/35	14OCT2020	01NOV2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/
C4591001 1231 12312914 (ARG/50/M)	Placebo	Dose 2/43	26OCT2020		Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever	Pos/
C4591001 1231 12313182 (ARG/33/M)	Placebo	Dose 2/10	20SEP2020	19OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat New or increased shortness of breath	Pos/
C4591001 1231 12313296 (ARG/49/F)	Placebo	Dose 2/25	04OCT2020	20OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/
C4591001 1231 12313400 (ARG/46/M)	Placebo	Dose 2/37	19OCT2020	28OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313422 (ARG/34/M)	Placebo	Dose 2/44	28OCT2020		Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12313520 (ARG/28/F)	Placebo	Dose 2/8	22SEP2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Diarrhea New or increased cough New loss of taste or smell Sore throat	Pos/
C4591001 1231 12313668 (ARG/33/M)	Placebo	Dose 2/12	24SEP2020	02OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/
C4591001 1231 12313787 (ARG/58/M)	Placebo	Dose 2/48	02NOV2020	05NOV2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1231 12313895 (ARG/50/F)	Placebo	Dose 2/21	03OCT2020	17OCT2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314112 (ARG/52/M)	Placebo	Dose 2/42	28OCT2020	02NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1231 12314308 (ARG/31/F)	Placebo	Dose 2/15	30SEP2020	11OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Vomiting	Pos/
C4591001 1231 12314534 (ARG/18/F)	Placebo	Dose 2/21	05OCT2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12314622 (ARG/32/F)	Placebo	Dose 2/15	01OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12315636 (ARG/53/F)	Placebo	Dose 2/35	23OCT2020		Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/
C4591001 1231 12315637 (ARG/40/F)	Placebo	Dose 2/11	29SEP2020	08OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1235 12351093 (USA/30/F)	BNT162b2 (30 µg)	Dose 2/32	08NOV2020	14NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1241 12412017 (BRA/59/M)	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/Pos
C4591001 1241 12412018 (BRA/55/F)	Placebo	Dose 2/8	28OCT2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/Pos
C4591001 1251 12511159 (USA/37/F)	Placebo	Dose 2/26	26OCT2020	29OCT2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain New loss of taste or smell	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441092 (ARG/64/M)	Placebo	Dose 2/23	03NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 4444 44441144 (ARG/38/M)	Placebo	Dose 2/26	07NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell Diarrhea	Pos/
C4591001 4444 44441204 (ARG/59/F)	BNT162b2 (30 µg)	Dose 2/21	02NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 4444 44441224 (ARG/52/M)	Placebo	Dose 2/13	25OCT2020		Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain	Pos/

090177e1959af315\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.2 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441563 (ARG/38/M)	Placebo	Dose 2/8	21OCT2020		Neg/Neg/Neg	New loss of taste or smell Diarrhea	Pos/

Abbreviations: ARG = Argentina; BRA = Brazil; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (16:08) Source Data: adsympt Table Generation: 18NOV2020 (11:58)

(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_Efficacy_FA_164/adsympt_1001_sympt_wo_d2_eval

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1003 10031122 (USA/48/M)	Placebo	Dose 2/77	05NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Chills	
C4591001 1006 10061012 (USA/53/M)	Placebo	Dose 2/68	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased shortness of breath	
						New or increased muscle pain	
C4591001 1006 10061066 (USA/39/F)	Placebo	Dose 2/59	11NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061084 (USA/27/F)	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
C4591001 1006 10061091 (USA/20/F)	Placebo	Dose 2/50	30OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1006 10061114 (USA/21/M)	Placebo	Dose 2/35	20OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased muscle pain	
						New loss of taste or smell	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081011 (USA/55/F)	Placebo	Dose 2/52	22OCT2020	31OCT2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 1008 10081048 (USA/38/F)	Placebo	Dose 2/60	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1008 10081130 (USA/52/F)	Placebo	Dose 2/32	17OCT2020	29OCT2020	Neg/Neg/Neg	Sore throat New or increased shortness of breath	Pos/
C4591001 1008 10081214 (USA/62/M)	Placebo	Dose 2/42	09NOV2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1008 10081319 (USA/79/F)	Placebo	Dose 2/31	04NOV2020		Neg/Neg/Neg	Chills	Pos/
C4591001 1008 10081356 (USA/63/M)	Placebo	Dose 2/25	31OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1009 10091128 (USA/51/M)	Placebo	Dose 2/30	15OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1013 10131288 (USA/53/M)	Placebo	Dose 2/11	25SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1013 10131475 (USA/49/F)	Placebo	Dose 2/23	22OCT2020	25OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1016 10161003 (USA/23/F)	Placebo	Dose 2/57	14OCT2020		Neg/Neg/Neg	Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161004 (USA/51/F)	BNT162b2 (30 µg)	Dose 2/58	15OCT2020	22OCT2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell New loss of taste or smell	Pos/
C4591001 1016 10161017 (USA/18/F)	Placebo	Dose 2/19	07SEP2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1016 10161035 (USA/70/F)	Placebo	Dose 2/67	29OCT2020	29OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell New or increased cough	Pos/
C4591001 1016 10161048 (USA/52/F)	Placebo	Dose 2/75	06NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1016 10161183 (USA/31/F)	Placebo	Dose 2/32	16OCT2020	01NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/ (R1 Pos)

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161207 (USA/62/F)	Placebo	Dose 2/27	14OCT2020		Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/ cough
C4591001 1016 10161305 (USA/16/M)	Placebo	Dose 2/8	09NOV2020		Neg/Neg/Pos	Chills New or increased muscle pain Sore throat	Pos/ cough
C4591001 1018 10181198 (USA/50/F)	Placebo	Dose 2/55	04NOV2020	05NOV2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/ cough
C4591001 1019 10191038 (USA/47/F)	Placebo	Dose 2/61	03NOV2020		Neg/Neg/Neg	New or increased cough Fever	Pos/ cough

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1019 10191184 (USA/52/M)	Placebo	Dose 2/36	05NOV2020		Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased muscle pain Vomiting	Pos/
C4591001 1028 10281038 (USA/53/F)	Placebo	Dose 2/31	10OCT2020	22OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1028 10281100 (USA/47/F)	Placebo	Dose 2/19	11OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1028 10281132 (USA/61/M)	Placebo	Dose 2/14	11OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1028 10281138 (USA/38/F)	Placebo	Dose 2/25	23OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/
						Chills Sore throat	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1037 10371036 (USA/62/M)	Placebo	Dose 2/52	31OCT2020		Neg/Neg/Neg	Diarrhea Fever	Pos/
C4591001 1037 10371280 (USA/58/M)	Placebo	Dose 2/28	10NOV2020		Neg/Neg/Neg	New or increased cough Chills Fever	Pos/
C4591001 1038 10381051 (USA/69/M)	Placebo	Dose 2/51	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1039 10391025 (USA/55/F)	Placebo	Dose 2/40	25OCT2020	03NOV2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 1046 10461058 (USA/44/F)	Placebo	Dose 2/62	09NOV2020		Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1047 10471024 (USA/63/F)	BNT162b2 (30 µg)	Dose 2/37	16OCT2020	18OCT2020	Neg/Neg/Neg	Fever Diarrhea Vomiting	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1068 10681082 (USA/58/M)	Placebo	Dose 2/42	01NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						New or increased shortness of breath	
						Sore throat	
C4591001 1068 10681110 (USA/30/F)	Placebo	Dose 2/22	16OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						New loss of taste or smell	
C4591001 1071 10711022 (USA/47/M)	Placebo	Dose 2/72	10NOV2020		Neg/Neg/Neg	Fever	Pos/
						Chills	
						New or increased muscle pain	
						Sore throat	
C4591001 1071 10711058 (USA/72/F)	Placebo	Dose 2/60	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1072 10721057 (USA/70/M)	Placebo	Dose 2/41	26OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1077 10771195 (USA/73/F)	Placebo	Dose 2/40	01NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1079 10791046 (USA/55/F)	Placebo	Dose 2/62	26OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1079 10791054 (USA/28/F)	Placebo	Dose 2/63	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1081 10811151 (USA/79/F)	Placebo	Dose 2/10	30SEP2020	14OCT2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1082 10821016 (USA/46/F)	Placebo	Dose 2/44	06OCT2020	27OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1085 10851293 (USA/63/F)	Placebo	Dose 2/37	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1088 10881219 (USA/63/M)	Placebo	Dose 2/17	25OCT2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell Fever	Pos/
						New or increased cough	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1088 10881233 (USA/47/M)	Placebo	Dose 2/15	02NOV2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/
C4591001 1089 10891235 (USA/29/F)	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	New or increased cough Chills Sore throat	Pos/
C4591001 1090 10901121 (USA/58/F)	Placebo	Dose 2/49	18OCT2020	22OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1090 10901353 (USA/63/M)	Placebo	Dose 2/40	08NOV2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1091 10911203 (USA/43/M)	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Unk/Pos
C4591001 1092 10921021 (USA/60/F)	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1092 10921130 (USA/53/M)	Placebo	Dose 2/18	09OCT2020		Neg/Neg/Neg	Chills New or increased muscle pain Fever	Pos/
C4591001 1093 10931081 (USA/67/F)	Placebo	Dose 2/19	05OCT2020	19OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea	Pos/
C4591001 1095 10951238 (USA/63/F)	Placebo	Dose 2/19	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1095 10951260 (USA/25/M)	Placebo	Dose 2/9	05NOV2020		Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1096 10961172 (USA/51/M)	Placebo	Dose 2/49	06NOV2020	08NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1096 10961258 (USA/55/F)	Placebo	Dose 2/25	22OCT2020		Neg/Neg/Neg	New or increased cough New or increased cough	Pos/Pos
C4591001 1098 10981062 (USA/63/F)	Placebo	Dose 2/32	17OCT2020	20OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/
C4591001 1101 11011095 (USA/60/M)	Placebo	Dose 2/20	02NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1107 11071171 (USA/39/M)	Placebo	Dose 2/58	10NOV2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1109 11091067 (USA/42/M)	Placebo	Dose 2/84	11NOV2020		Neg/Neg/Neg	Chills New or increased shortness of breath	Pos/
C4591001 1109 11091092 (USA/18/M)	Placebo	Dose 2/70	31OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1109 11091323 (USA/64/M)	Placebo	Dose 2/47	31OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/
C4591001 1109 11091416 (USA/46/F)	Placebo	Dose 2/41	03NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
C4591001 1109 11091448 (USA/46/F)	Placebo	Dose 2/9	06OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/ (R1 Pos)
C4591001 1109 11091482 (USA/63/M)	Placebo	Dose 2/28	29OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1110 11101050 (USA/47/M)	BNT162b2 (30 µg)	Dose 2/76	10NOV2020		Neg/Neg/Neg	New loss of taste or smell New or increased cough Chills	Pos/
C4591001 1110 11101136 (USA/62/M)	Placebo	Dose 2/52	04NOV2020		Neg/Neg/Neg	Sore throat New or increased cough Chills	Pos/
C4591001 1110 11101162 (USA/51/M)	BNT162b2 (30 µg)	Dose 2/34	24OCT2020		Neg/Neg/Neg	Diarrhea New or increased cough	Pos/
C4591001 1111 11111010 (USA/75/M)	Placebo	Dose 2/45	04OCT2020	05OCT2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1116 11161075 (USA/73/M)	Placebo	Dose 2/43	03NOV2020		Neg/Neg/Neg	Chills New or increased cough	Pos/
C4591001 1117 11171010 (USA/72/F)	Placebo	Dose 2/34	11OCT2020	19OCT2020	Neg/Neg/Neg	New or increased shortness of breath Chills Fever	Pos/
						New or increased cough	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1118 11181088 (USA/73/M)	Placebo	Dose 2/36	20OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1120 11201115 (USA/19/F)	Placebo	Dose 2/73	06NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1121 11211105 (USA/52/M)	Placebo	Dose 2/39	05NOV2020		Neg/Unk/Neg	Fever New or increased cough Sore throat	Pos/
C4591001 1122 11221025 (USA/40/M)	Placebo	Dose 2/32	01NOV2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/
C4591001 1123 11231025 (USA/60/F)	Placebo	Dose 2/77	08NOV2020		Neg/Neg/Unk	New or increased cough Sore throat	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231073 (USA/25/F)	Placebo	Dose 2/10	10SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/Pos
C4591001 1123 11231086 (USA/35/F)	Placebo	Dose 2/57	27OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1123 11231117 (USA/55/F)	Placebo	Dose 2/64	10NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain	Pos/
C4591001 1123 11231214 (USA/60/F)	Placebo	Dose 2/34	26OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat	Pos/
C4591001 1123 11231234 (USA/29/M)	Placebo	Dose 2/32	02NOV2020		Unk/Neg/Neg	New or increased cough New or increased muscle pain	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231255 (USA/76/M)	Placebo	Dose 2/20	24OCT2020		Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1123 11231256 (USA/72/F)	Placebo	Dose 2/24	28OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1123 11231284 (USA/67/M)	Placebo	Dose 2/12	24OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1125 11251006 (USA/35/M)	Placebo	Dose 2/42	11OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
C4591001 1125 11251014 (USA/45/F)	Placebo	Dose 2/59	30OCT2020		Neg/Neg/Neg	New or increased cough Chills Fever	Pos/
						New or increased cough New or increased shortness of breath Chills New or increased muscle pain	

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251023 (USA/49/M)	Placebo	Dose 2/56	27OCT2020		Neg/Neg/Neg	Diarrhea New or increased cough New or increased shortness of breath Chills New or increased muscle pain	Pos/
C4591001 1125 11251028 (USA/39/F)	Placebo	Dose 2/27	29SEP2020	02OCT2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Sore throat	Pos/
C4591001 1125 11251049 (USA/52/M)	Placebo	Dose 2/50	27OCT2020		Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/
C4591001 1125 11251109 (USA/46/F)	Placebo	Dose 2/51	04NOV2020		Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain Diarrhea	Pos/
C4591001 1125 11251114 (USA/59/M)	Placebo	Dose 2/38	22OCT2020		Neg/Neg/Neg	Fever	Pos/Pos

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251124 (USA/39/M)	Placebo	Dose 2/53	08NOV2020	10NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/
C4591001 1125 11251215 (USA/43/M)	Placebo	Dose 2/25	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1126 11261017 (USA/34/F)	Placebo	Dose 2/50	20OCT2020		Neg/Neg/Neg	Fever New or increased muscle pain	Pos/
C4591001 1128 11281165 (USA/26/F)	Placebo	Dose 2/46	29OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1131 11311100 (USA/64/M)	Placebo	Dose 2/58	12NOV2020		Neg/Neg/Neg	Fever Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1131 11311138 (USA/45/F)	Placebo	Dose 2/45	07NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath	Pos/
C4591001 1133 11331209 (USA/30/M)	Placebo	Dose 2/32	10OCT2020		Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1134 11341022 (USA/66/M)	Placebo	Dose 2/29	29SEP2020	03OCT2020	Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1135 11351207 (USA/33/F)	Placebo	Dose 2/30	13OCT2020		Neg/Neg/Neg	Sore throat New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1141 11411088 (USA/52/M)	Placebo	Dose 2/29	07OCT2020		Neg/Neg/Neg	Diarrhea Fever	Pos/
C4591001 1141 11411161 (USA/25/F)	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	Chills Sore throat Fever	Pos/
C4591001 1141 11411162 (USA/20/M)	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Diarrhea Vomiting	Pos/
C4591001 1149 11491113 (USA/69/M) µg)	BNT162b2 (30 µg)	Dose 2/44	23OCT2020	24OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1152 11521363 (USA/19/M)	Placebo	Dose 2/9	06OCT2020		Neg/Neg/Neg	Chills Vomiting New or increased cough	Pos/
C4591001 1152 11521372 (USA/28/F)	Placebo	Dose 2/32	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1162 11621075 (USA/40/F)	Placebo	Dose 2/67	06NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Sore throat New or increased muscle pain	Pos/
C4591001 1163 11631113 (USA/25/M)	Placebo	Dose 2/43	14OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1163 11631135 (USA/42/M)	Placebo	Dose 2/21	30SEP2020	02OCT2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/
C4591001 1167 11671152 (USA/41/F)	Placebo	Dose 2/26	20OCT2020		Neg/Neg/Neg	New or increased muscle pain Diarrhea Fever	Pos/Pos

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1167 11671157 (USA/58/M)	Placebo	Dose 2/16	14OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/
C4591001 1168 11681004 (USA/54/M)	Placebo	Dose 2/67	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
C4591001 1168 11681007 (USA/33/F)	Placebo	Dose 2/36	06OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain New or increased cough New or increased shortness of breath	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681008 (USA/37/M)	Placebo	Dose 2/35	05OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/ cough
C4591001 1168 11681114 (USA/46/F)	Placebo	Dose 2/23	13OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1168 11681117 (USA/37/M)	Placebo	Dose 2/45	04NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/ Fever
C4591001 1169 11691007 (USA/28/F)	Placebo	Dose 2/19	11OCT2020		Neg/Unk/Neg	New or increased muscle pain New or increased shortness of breath	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1170 11701089 (USA/25/F)	Placebo	Dose 2/16	01OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 1178 11781065 (USA/48/M)	Placebo	Dose 2/23	13OCT2020	25OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1178 11781238 (USA/60/F)	Placebo	Dose 2/16	29OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1178 11781280 (USA/58/M)	Placebo	Dose 2/9	03NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1179 11791085 (USA/34/M)	Placebo	Dose 2/34	09NOV2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/
C4591001 1223 12231005 (USA/20/F)	Placebo	Dose 2/51	06NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1223 12231096 (USA/77/F)	Placebo	Dose 2/48	11NOV2020	12NOV2020	Neg/Neg/Neg	Chills Sore throat New or increased cough	Pos/
C4591001 1226 12261309 (BRA/61/M)	Placebo	Dose 2/40	20OCT2020	26OCT2020	Neg/Neg/Neg	Chills New or increased cough	Pos/
C4591001 1226 12261363 (BRA/48/F)	Placebo	Dose 2/23	03OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261599 (BRA/41/F)	BNT162b2 (30 µg)	Dose 2/36	06NOV2020		Neg/Neg/Neg	Vomiting New or increased cough	Pos/
C4591001 1226 12261624 (BRA/52/M)	Placebo	Dose 2/34	02NOV2020		Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/
C4591001 1226 12261660 (BRA/27/F)	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1226 12261964 (BRA/27/F)	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	New or increased muscle pain New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1226 12262111 (BRA/51/M)	Placebo	Dose 2/12	10NOV2020	12NOV2020	Neg/Neg/Neg	Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311043 (ARG/46/M)	Placebo	Dose 2/40	10OCT2020	11OCT2020	Neg/Neg/Neg	New or increased cough Chills	Pos/
C4591001 1231 12311267 (ARG/67/M)	Placebo	Dose 2/24	26SEP2020	07OCT2020	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/
C4591001 1231 12311407 (ARG/63/M)	Placebo	Dose 2/24	27SEP2020	06OCT2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Diarrhea	Pos/
C4591001 1231 12311531 (ARG/35/M)	Placebo	Dose 2/9	16SEP2020	27SEP2020	Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1231 12311556 (ARG/24/M)	Placebo	Dose 2/45	21OCT2020	09NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12311560 (ARG/44/M)	Placebo	Dose 2/70	12NOV2020		Neg/Neg/Neg	Fever New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311651 (ARG/52/F)	Placebo	Dose 2/8	14SEP2020	01OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Vomiting	Pos/
C4591001 1231 12311664 (ARG/34/F)	Placebo	Dose 2/9	15SEP2020	03OCT2020	Neg/Neg/Neg	Fever New or increased cough	Pos/
C4591001 1231 12311754 (ARG/54/M)	Placebo	Dose 2/38	14OCT2020	25OCT2020	Neg/Neg/Neg	Fever New or increased muscle pain Sore throat	Pos/
C4591001 1231 12311764 (ARG/34/M)	Placebo	Dose 2/63	09NOV2020	09NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12311982 (ARG/41/F)	Placebo	Dose 2/37	14OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312479 (ARG/43/M)	Placebo	Dose 2/30	09OCT2020		Neg/Neg/Neg	New or increased cough Chills	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312507 (ARG/47/F)	Placebo	Dose 2/10	17SEP2020	28SEP2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased muscle pain	Pos/
C4591001 1231 12312630 (ARG/39/F)	Placebo	Dose 2/44	23OCT2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1231 12312635 (ARG/71/M)	Placebo	Dose 2/27	04OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12312867 (ARG/40/F)	Placebo	Dose 2/35	14OCT2020	01NOV2020	Neg/Neg/Neg	Chills Sore throat Fever New loss of taste or smell	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312914 (ARG/50/M)	Placebo	Dose 2/43	26OCT2020		Neg/Neg/Neg	Diarrhea Fever	Pos/
C4591001 1231 12313182 (ARG/33/M)	Placebo	Dose 2/10	20SEP2020	19OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/ shortness of breath
C4591001 1231 12313296 (ARG/49/F)	Placebo	Dose 2/25	04OCT2020	20OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/ shortness of breath
C4591001 1231 12313400 (ARG/46/M)	Placebo	Dose 2/37	19OCT2020	28OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased shortness of breath Chills	Pos/ shortness of breath
C4591001 1231 12313422 (ARG/34/M)	Placebo	Dose 2/44	28OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313520 (ARG/28/F)	Placebo	Dose 2/8	22SEP2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Diarrhea	Pos/ cough
C4591001 1231 12313668 (ARG/33/M)	Placebo	Dose 2/12	24SEP2020	02OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/ smell
C4591001 1231 12313787 (ARG/58/M)	Placebo	Dose 2/48	02NOV2020	05NOV2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/ cough
C4591001 1231 12313895 (ARG/50/F)	Placebo	Dose 2/21	03OCT2020	17OCT2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain New loss of taste or smell	Pos/ cough
C4591001 1231 12314112 (ARG/52/M)	Placebo	Dose 2/42	28OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/ cough
C4591001 1231 12314308 (ARG/31/F)	Placebo	Dose 2/15	30SEP2020	11OCT2020	Neg/Neg/Neg	New or increased cough	Pos/ cough

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314477 (ARG/36/M)	Placebo	Dose 2/16	03OCT2020	15OCT2020	Pos/Neg/Neg	New or increased muscle pain Sore throat Vomiting New or increased cough	Pos/
C4591001 1231 12314534 (ARG/18/F)	Placebo	Dose 2/21	05OCT2020	09OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/
C4591001 1231 12314622 (ARG/32/F)	Placebo	Dose 2/15	01OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12315636 (ARG/53/F)	Placebo	Dose 2/35	23OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12315637 (ARG/40/F)	Placebo	Dose 2/11	29SEP2020	08OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 1235 12351093 (USA/30/F)	BNT162b2 (30 µg)	Dose 2/32	08NOV2020	14NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1241 12411885 (BRA/23/M)	BNT162b2 (30 µg)	Dose 2/14	22OCT2020	24OCT2020	Pos/Neg/Neg	Sore throat	Pos/Neg
C4591001 1241 12412017 (BRA/59/M)	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	Fever	Pos/Pos
C4591001 1241 12412018 (BRA/55/F)	Placebo	Dose 2/8	28OCT2020		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/Pos
C4591001 1247 12471085 (ZAF/54/F)	Placebo	Dose 2/12	30OCT2020	03NOV2020	Neg/Unk/Neg	Sore throat New or increased cough Chills Diarrhea	Pos/
C4591001 1251 12511159 (USA/37/F)	Placebo	Dose 2/26	26OCT2020	29OCT2020	Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441092 (ARG/64/M)	Placebo	Dose 2/23	03NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/
C4591001 4444 44441144 (ARG/38/M)	Placebo	Dose 2/26	07NOV2020		Neg/Neg/Neg	Sore throat Fever	Pos/
C4591001 4444 44441204 (ARG/59/F)	BNT162b2 (30 µg)	Dose 2/21	02NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea New or increased muscle pain New loss of taste or smell	Pos/
C4591001 4444 44441224 (ARG/52/M)	Placebo	Dose 2/13	25OCT2020		Neg/Neg/Neg	Fever	Pos/

16.2.8.3 Listing of Subjects With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441563 (ARG/38/M)	Placebo	Dose 2/8	21OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell Diarrhea	Pos/

Abbreviations: ARG = Argentina; BRA = Brazil; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown; ZAF = South Africa.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (16:08) Source Data: adsympt Table Generation: 18NOV2020 (12:00)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_Efficacy_FA_164/adsympt_1001_sympt_d2_eval

16.2.8.4 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and Severe COVID-19 Signs, Symptoms, and Events – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1047 10471252 (USA/63/M)	Placebo	Dose 1/26	16OCT2020		Neg/Neg/Unk	SpO ₂ ≤ 93% on room air at sea level	Pos/
		Dose 1/26	16OCT2020			High-flow oxygen therapy	
C4591001 1116 11161253 (USA/61/M)	Placebo	Dose 1/11	28SEP2020		Neg/Neg/Pos	HR ≥ 125 beats/minute	Pos/
C4591001 1156 11561044 (USA/63/M)	Placebo	Dose 1/8	03SEP2020		Neg/Neg/Neg	Significant acute renal dysfunction	Pos/
		Dose 1/8	03SEP2020	09SEP2020		Significant acute hepatic dysfunction	
		Dose 1/10	05SEP2020			SpO ₂ ≤ 93% on room air at sea level	
		Dose 1/10	05SEP2020	09SEP2020		High-flow oxygen therapy	
		Dose 1/10	05SEP2020	19SEP2020		Admission to an ICU	
		Dose 1/19	14SEP2020			SpO ₂ ≤ 93% on room air at sea level	
		Dose 1/34	29SEP2020			SpO ₂ ≤ 93% on room air at sea level	
		Dose 1/36	01OCT2020			SpO ₂ ≤ 93% on room air at sea level	
C4591001 1221 12211002 (USA/43/M)	Placebo	Dose 2/2	03NOV2020		Neg/Neg/Unk	RR ≥ 30 breaths/minute	Unk/Pos
C4591001 1226 12261599 (BRA/41/F)*	BNT162b2 (30 µg)	Dose 2/37	07NOV2020		Neg/Neg/Neg	SpO ₂ ≤ 93% on room air at sea level	Pos/

090177e1959af314\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.4 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and Severe COVID-19 Signs, Symptoms, and Events – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261624 (BRA/52/M)*	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	SpO ₂ ≤ 93% on room air at sea level	Pos/
C4591001 1231 12312914 (ARG/50/M)*	Placebo	Dose 2/54	06NOV2020		Neg/Neg/Neg	SpO ₂ ≤ 93% on room air at sea level	Pos/
C4591001 1231 12313422 (ARG/34/M)*	Placebo	Dose 2/53	06NOV2020	12NOV2020	Neg/Neg/Neg	Needs mechanical ventilation	Pos/
		Dose 2/53	06NOV2020			Admission to an ICU	
		Dose 2/54	07NOV2020			PaO ₂ /FiO ₂	
C4591001 1235 12351071 (USA/50/M)	Placebo	Dose 1/9	22SEP2020	26SEP2020	Neg/Neg/Unk	Admission to an ICU	Pos/
		Dose 1/11	24SEP2020			SpO ₂ ≤ 93% on room air at sea level	
C4591001 4444 44442304 (ARG/49/M)	Placebo	Dose 2/13	27OCT2020		Neg/Neg/Neg	HR ≥ 125 beats/minute	Pos/

Abbreviations: ARG = Argentina; BRA = Brazil; HR = heart rate; ICU = intensive care unit; FiO₂ = fraction of inspired oxygen; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = Negative; PaO₂ = partial pressure of oxygen, arterial; Pos = Positive; RR = respiratory rate; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO₂ = oxygen saturation as measured by pulse oximetry; Unk = Unknown.

Note: * indicates subject in the evaluable efficacy (7 days) population with first severe COVID-19 occurrence from 7 days after Dose 2 and without evidence of infection prior to 7 days after Dose 2.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert® Xpress SARS-CoV-2 test, Roche cobas® SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (16:08) Source Data: adsympt Table Generation: 18NOV2020 (18:25)

(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_Efficacy_FA_164/adsympt_1001_sympt_sev_d1_aai

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1003 10031122 (USA/48/M)*	Placebo	Dose 2/77	05NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Chills	
C4591001 1005 10051341 (USA/23/F)	Placebo	Dose 1/2	22OCT2020		Neg/Pos/Neg	New or increased cough	Pos/
						New or increased shortness of breath	
						New loss of taste or smell	
						Sore throat	
						Diarrhea	
						Headache#	
						Nasal congestion#	
C4591001 1005 10051403 (USA/66/F)	BNT162b2 (30 µg)	Dose 1/4	07NOV2020		Neg/Neg/Unk	New or increased cough	Pos/
						Sore throat	
						Runny nose#	
C4591001 1006 10061012 (USA/53/M)*	Placebo	Dose 2/68	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						New or increased shortness of breath	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1006 10061066 (USA/39/F)*	Placebo	Dose 2/59	11NOV2020		Neg/Neg/Neg	New or increased muscle pain Headache# New or increased cough	Pos/
C4591001 1006 10061084 (USA/27/F)*	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	Sore throat Fatigue# Headache# Nasal congestion# Fever	Pos/
C4591001 1006 10061091 (USA/20/F)*	Placebo	Dose 2/50	30OCT2020		Neg/Neg/Neg	New or increased cough New or increased cough	Pos/
C4591001 1006 10061114 (USA/21/M)*	Placebo	Dose 2/35	20OCT2020		Neg/Neg/Neg	Sore throat Nasal congestion# New or increased cough New or increased muscle pain New loss of taste or smell	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1007 10071407 (USA/41/M)	Placebo	Dose 1/12	02NOV2020		Neg/Neg/Unk	Sore throat Nasal congestion# New or increased cough	Pos/
C4591001 1007 10071409 (USA/13/M)	BNT162b2 (30 µg)	Dose 1/10	31OCT2020	04NOV2020	Neg/Neg/Unk	Sore throat Diarrhea Fever	Pos/
C4591001 1008 10081011 (USA/55/F)*	Placebo	Dose 2/52	22OCT2020	31OCT2020	Neg/Neg/Neg	Headache# Runny nose# New loss of taste or smell	Pos/
C4591001 1008 10081048 (USA/38/F)*	Placebo	Dose 2/60	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Fatigue# Headache# Nasal congestion#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081130 (USA/52/F)*	Placebo	Dose 2/32	17OCT2020	29OCT2020	Neg/Neg/Neg	Runny nose# New or increased shortness of breath	Pos/
C4591001 1008 10081214 (USA/62/M)*	Placebo	Dose 2/42	09NOV2020		Neg/Neg/Neg	Headache# Fever	Pos/
C4591001 1008 10081302 (USA/64/F)	Placebo	Dose 2/6	07OCT2020		Neg/Neg/Pos	New or increased cough New or increased shortness of breath New or increased muscle pain Fatigue# Headache#	Pos/
C4591001 1008 10081319 (USA/79/F)*	Placebo	Dose 2/31	04NOV2020		Neg/Neg/Neg	Headache# Chills	Pos/
C4591001 1008 10081338 (USA/53/M)	Placebo	Dose 2/1	06OCT2020	16OCT2020	Neg/Neg/Neg	Fatigue# Runny nose# Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081356 (USA/63/M)*	Placebo	Dose 2/25	31OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fatigue# Nasal congestion#	Pos/ cough
C4591001 1008 10081529 (USA/38/M)	BNT162b2 (30 µg)	Dose 1/2	26SEP2020		Neg/Neg/Pos	New loss of taste or smell Runny nose# New or increased cough New loss of taste or smell Sore throat Fatigue# Nasal congestion# Runny nose#	Pos/ cough
C4591001 1008 10081580 (USA/38/M)	Placebo	Dose 2/7	03NOV2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1008 10081639 (USA/63/M)	Placebo	Dose 1/6	24OCT2020		Neg/Neg/Unk	Fatigue# Headache# New or increased cough Sore throat Headache# Nasal congestion#	Pos/
C4591001 1008 10081721 (USA/37/F)	Placebo	Dose 1/13	10NOV2020		Neg/Neg/Unk	Sore throat Nasal congestion#	Pos/
C4591001 1009 10091128 (USA/51/M)*	Placebo	Dose 2/30	15OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1009 10091211 (USA/44/F)	Placebo	Dose 1/19	03NOV2020		Neg/Neg/Unk	New or increased cough Chills Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1009 10091257 (USA/21/F)	Placebo	Dose 1/10	05NOV2020		Neg/Neg/Unk	New or increased cough New or increased shortness of breath Chills Fatigue#	Pos/
C4591001 1011 10111174 (USA/24/M)	Placebo	Dose 2/7	04NOV2020		Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain Sore throat Headache# Nasal congestion#	Pos/
C4591001 1013 10131288 (USA/53/M)*	Placebo	Dose 2/11	25SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Fatigue#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1013 10131475 (USA/49/F)*	Placebo	Dose 2/23	22OCT2020	25OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Fatigue# Headache#	Pos/
C4591001 1013 10131670 (USA/41/M)†	BNT162b2 (30 µg)	Dose 1/4	11OCT2020		Neg/Pos/Neg	New loss of taste or smell Fatigue# Nasal congestion#	Pos/
C4591001 1016 10161003 (USA/23/F)*	Placebo	Dose 2/57	14OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New loss of taste or smell Headache#	Pos/
C4591001 1016 10161004 (USA/51/F)*	BNT162b2 (30 µg)	Dose 2/58	15OCT2020	22OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161017 (USA/18/F)*	Placebo	Dose 2/19	07SEP2020		Neg/Neg/Neg	Headache# Nasal congestion# Fever	Pos/
C4591001 1016 10161035 (USA/70/F)*	Placebo	Dose 2/67	29OCT2020	29OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Headache# New or increased cough	Pos/
C4591001 1016 10161048 (USA/52/F)*	Placebo	Dose 2/75	06NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/
C4591001 1016 10161183 (USA/31/F)*	Placebo	Dose 2/32	16OCT2020	01NOV2020	Neg/Neg/Neg	Sore throat Fever New or increased cough Chills	Pos/ (R1 Pos)

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161207 (USA/62/F)*	Placebo	Dose 2/27	14OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting Headache#	Pos/ cough
C4591001 1016 10161305 (USA/16/M)	Placebo	Dose 2/8	09NOV2020		Neg/Neg/Pos	Chills New or increased muscle pain Sore throat Fatigue# Nasal congestion#	Pos/ cough
C4591001 1016 10161316 (USA/15/M)	Placebo	Dose 1/17	01NOV2020		Neg/Neg/Unk	New loss of taste or smell New or increased cough Chills New or increased muscle pain	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1016 10161319 (USA/12/F)	Placebo	Dose 2/6	09NOV2020		Neg/Neg/Neg	New loss of taste or smell Sore throat Diarrhea Nasal congestion# Fever	Pos/
C4591001 1016 10161341 (USA/44/F)	BNT162b2 (30 µg)	Dose 1/10	31OCT2020		Neg/Neg/Pos	New or increased cough Chills New loss of taste or smell Sore throat Nasal congestion# New or increased cough	Pos/
C4591001 1018 10181198 (USA/50/F)*	Placebo	Dose 2/55	04NOV2020	05NOV2020	Neg/Neg/Neg	New or increased shortness of breath Sore throat Diarrhea Nasal congestion# Fever New or increased cough	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1019 10191038 (USA/47/F)*	Placebo	Dose 2/61	03NOV2020		Neg/Neg/Neg	Nasal congestion# Fever	Pos/
C4591001 1019 10191184 (USA/52/M)*	Placebo	Dose 2/36	05NOV2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell Fatigue# New or increased cough	Pos/
C4591001 1024 10241130 (USA/65/M)†	Placebo	Dose 1/9	28OCT2020		Neg/Neg/Pos	New or increased muscle pain Vomiting Nausea# Fever	Pos/
C4591001 1028 10281038 (USA/53/F)*	Placebo	Dose 2/31	10OCT2020	22OCT2020	Neg/Neg/Neg	New or increased muscle pain Fever New or increased cough Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1028 10281100 (USA/47/F)*	Placebo	Dose 2/19	11OCT2020		Neg/Neg/Neg	Runny nose# New or increased cough	Pos/
C4591001 1028 10281132 (USA/61/M)*	Placebo	Dose 2/14	11OCT2020		Neg/Neg/Neg	Runny nose# Fever New or increased cough Chills New or increased muscle pain Sore throat	Pos/
C4591001 1028 10281138 (USA/38/F)*	Placebo	Dose 2/25	23OCT2020		Neg/Neg/Neg	Fever Chills Sore throat Diarrhea Nasal congestion# Runny nose#	Pos/
C4591001 1028 10281193 (USA/60/F)	Placebo	Dose 2/7	14OCT2020	09NOV2020	Neg/Neg/Neg	New or increased cough Chills Nasal congestion#	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1028 10281229 (USA/45/M)	Placebo	Dose 2/3	17OCT2020		Neg/Neg/Neg	Runny nose# Nausea# New or increased cough Chills New loss of taste or smell Sore throat Vomiting Fatigue#	Pos/
C4591001 1028 10281250 (USA/18/M)	Placebo	Dose 1/11	18OCT2020		Neg/Neg/Pos	Sore throat	Pos/
C4591001 1028 10281294 (USA/23/F)	Placebo	Dose 1/7	04NOV2020		Neg/Neg/Unk	New or increased cough New or increased shortness of breath New or increased muscle pain Fatigue# Nausea#	Pos/
C4591001 1036 10361078 (USA/20/M)	Placebo	Dose 2/2	01OCT2020		Neg/Neg/Pos	New loss of taste or smell	Pos/
C4591001 1037 10371036 (USA/62/M)*	Placebo	Dose 2/52	31OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1037 10371280 (USA/58/M)*	Placebo	Dose 2/28	10NOV2020		Neg/Neg/Neg	New or increased cough Chills Fatigue# Nasal congestion# Fever	Pos/
C4591001 1038 10381051 (USA/69/M)*	Placebo	Dose 2/51	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fatigue# Headache#	Pos/ cough
C4591001 1038 10381103 (USA/43/F)	Placebo	Dose 2/5	04OCT2020		Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/ smell
C4591001 1039 10391021 (USA/26/F)	Placebo	Dose 1/1	25AUG2020	14SEP2020	Neg/Pos/Pos	Fever	Pos/ New or increased cough

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1039 10391025 (USA/55/F)*	Placebo	Dose 2/40	25OCT2020	03NOV2020	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell Sore throat New loss of taste or smell	Pos/
C4591001 1046 10461058 (USA/44/F)*	Placebo	Dose 2/62	09NOV2020		Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/
C4591001 1047 10471024 (USA/63/F)*	BNT162b2 (30 µg)	Dose 2/37	16OCT2020	18OCT2020	Neg/Neg/Neg	Fatigue# Nasal congestion# Fever	Pos/
C4591001 1047 10471252 (USA/63/M)	Placebo	Dose 1/22	12OCT2020		Neg/Neg/Unk	Diarrhea Vomiting Nausea# Fever	Pos/
						New or increased cough New or increased shortness of breath	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1068 10681033 (USA/65/M)	Placebo	Dose 1/23	15SEP2020	21OCT2020	Neg/Neg/Pos	New or increased muscle pain Diarrhea Headache# Fever	Pos/
C4591001 1068 10681082 (USA/58/M)*	Placebo	Dose 2/42	01NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Diarrhea Nasal congestion# Fever	Pos/
C4591001 1068 10681110 (USA/30/F)*	Placebo	Dose 2/22	16OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Sore throat New or increased cough New loss of taste or smell	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1071 10711022 (USA/47/M)*	Placebo	Dose 2/72	10NOV2020		Neg/Neg/Neg	Nasal congestion# Fever	Pos/
						Chills New or increased muscle pain Sore throat Headache#	
C4591001 1071 10711058 (USA/72/F)*	Placebo	Dose 2/60	06NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat	
C4591001 1071 10711216 (USA/64/F)	Placebo	Dose 1/4	12OCT2020	17OCT2020	Neg/Neg/Unk	Fever	Pos/
						New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	
C4591001 1071 10711228 (USA/66/F)	BNT162b2 (30 µg)	Dose 2/5	09NOV2020		Neg/Neg/Pos	Fever	Pos/
						New or increased cough	

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1072 10721051 (USA/47/F)	Placebo	Dose 1/12	06SEP2020	20SEP2020	Neg/Neg/Unk	Fever	Pos/
						New or increased cough	
						New loss of taste or smell	
						Sore throat	
C4591001 1072 10721057 (USA/70/M)*	Placebo	Dose 2/41	26OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1077 10771195 (USA/73/F)*	Placebo	Dose 2/40	01NOV2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						New or increased muscle pain	
						Nasal congestion#	
C4591001 1079 10791046 (USA/55/F)*	Placebo	Dose 2/62	26OCT2020		Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1079 10791054 (USA/28/F)*	Placebo	Dose 2/63	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						Fatigue#	
C4591001 1079 10791162 (USA/20/M)	Placebo	Dose 2/45	09OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1081 10811151 (USA/79/F)*	Placebo	Dose 2/10	30SEP2020	14OCT2020	Neg/Neg/Neg	Sore throat Nausea# New or increased cough	Pos/
C4591001 1082 10821016 (USA/46/F)*	Placebo	Dose 2/44	06OCT2020	27OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1083 10831029 (USA/50/M)	Placebo	Dose 1/96	07NOV2020		Neg/Neg/Unk	New or increased cough Chills New or increased muscle pain New loss of taste or smell Fatigue#	Pos/
C4591001 1085 10851286 (USA/52/F)	Placebo	Dose 1/24	02OCT2020	13OCT2020	Neg/Neg/Pos	Chills Sore throat	Pos/
C4591001 1085 10851293 (USA/63/F)*	Placebo	Dose 2/37	07NOV2020		Neg/Neg/Neg	Fatigue# Nasal congestion# Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1087 10871089 (USA/21/F)	Placebo	Dose 1/19	04SEP2020	30SEP2020	Neg/Neg/Unk	New or increased cough New loss of taste or smell Fever	Pos/
C4591001 1087 10871209 (USA/50/F)	BNT162b2 (30 µg)	Dose 1/7	31AUG2020	03SEP2020	Neg/Neg/Unk	Fatigue# Fever	Pos/
C4591001 1088 10881219 (USA/63/M)*	Placebo	Dose 2/17	25OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Nasal congestion# Fever	Pos/
C4591001 1088 10881233 (USA/47/M)*	Placebo	Dose 2/15	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Headache# Fever	Pos/
						New or increased cough	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1089 10891217 (USA/64/F)	BNT162b2 (30 µg)	Dose 1/5	04SEP2020	12SEP2020	Neg/Neg/Pos	Chills Sore throat New or increased cough	Pos/
C4591001 1089 10891235 (USA/29/F)*	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	New or increased shortness of breath Fatigue# New or increased cough	Pos/
C4591001 1090 10901121 (USA/58/F)*	Placebo	Dose 2/49	18OCT2020	22OCT2020	Neg/Neg/Neg	Sore throat Headache# Fever	Pos/
C4591001 1090 10901353 (USA/63/M)*	Placebo	Dose 2/40	08NOV2020		Neg/Neg/Neg	New loss of taste or smell Nasal congestion# Fever	Pos/
C4591001 1091 10911014 (USA/52/M)	Placebo	Dose 2/76	03NOV2020		Neg/Neg/Neg	New or increased cough Fever	Pos/
						Chills	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1091 10911203 (USA/43/M)*	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	Diarrhea New or increased cough	Unk/Pos
C4591001 1091 10911387 (USA/17/F)	BNT162b2 (30 µg)	Dose 1/2	06NOV2020		Unk/Neg/Unk	New or increased muscle pain Fatigue# Fever	Pos/
C4591001 1092 10921021 (USA/60/F)*	Placebo	Dose 2/48	27OCT2020		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Headache# Nausea# Fever	Pos/
C4591001 1092 10921130 (USA/53/M)*	Placebo	Dose 2/18	09OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1092 10921158 (USA/23/M)	Placebo	Dose 1/10	12SEP2020	21SEP2020	Neg/Neg/Pos	New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea Headache#	Pos/ cough
C4591001 1092 10921268 (USA/64/F)	BNT162b2 (30 µg)	Dose 1/2	23OCT2020	28OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1093 10931014 (USA/68/M)	Placebo	Dose 2/1	08SEP2020	16SEP2020	Neg/Neg/Neg	New or increased muscle pain New or increased shortness of breath Chills New or increased muscle pain	Pos/
C4591001 1093 10931050 (USA/62/M)	Placebo	Dose 1/24	16SEP2020	10NOV2020	Neg/Neg/Unk	New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1093 10931063 (USA/38/M)*	Placebo	Dose 2/43	28OCT2020		Neg/Neg/Neg	New loss of taste or smell Fatigue# Nasal congestion# Runny nose# Fatigue#	Pos/
C4591001 1093 10931081 (USA/67/F)*	Placebo	Dose 2/19	05OCT2020	19OCT2020	Neg/Neg/Neg	Sore throat	Pos/
C4591001 1093 10931122 (USA/58/F)*	Placebo	Dose 2/9	08OCT2020		Neg/Neg/Neg	Fatigue# Headache# Nasal congestion# Runny nose# Fatigue#	Pos/
C4591001 1093 10931148 (USA/21/F)	Placebo	Dose 2/1	12OCT2020		Neg/Neg/Pos	Headache# New loss of taste or smell Diarrhea Nasal congestion#	Pos/
C4591001 1095 10951238 (USA/63/F)*	Placebo	Dose 2/19	02NOV2020		Neg/Neg/Neg	New or increased cough	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1095 10951260 (USA/25/M)*	Placebo	Dose 2/9	05NOV2020		Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1096 10961172 (USA/51/M)*	Placebo	Dose 2/49	06NOV2020	08NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Headache# Nasal congestion# Fever	Pos/
C4591001 1096 10961258 (USA/55/F)*	Placebo	Dose 2/25	22OCT2020		Neg/Neg/Neg	New or increased cough Fatigue# New or increased cough	Pos/Pos

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1096 10961388 (USA/17/F)	Placebo	Dose 1/4	12OCT2020	15OCT2020	Neg/Neg/Pos	New or increased muscle pain Sore throat Fatigue# Headache# Sore throat	Pos/
C4591001 1097 10971103 (USA/72/F)	Placebo	Dose 1/18	25SEP2020	03OCT2020	Neg/Neg/Pos	Headache# Fever	Pos/
C4591001 1097 10971104 (USA/73/M) µg)	BNT162b2 (30	Dose 1/18	25SEP2020	06OCT2020	Neg/Neg/Pos	New or increased cough New or increased muscle pain New loss of taste or smell Diarrhea Fever	Pos/
C4591001 1098 10981029 (USA/36/M) µg)	BNT162b2 (30	Dose 1/11	31AUG2020	01SEP2020	Neg/Neg/Unk	New or increased cough New loss of taste or smell Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1098 10981062 (USA/63/F)*	Placebo	Dose 2/32	17OCT2020	20OCT2020	Neg/Neg/Neg	New or increased muscle pain	Pos/
C4591001 1101 11011024 (USA/54/F)	Placebo	Dose 1/11	19SEP2020	07OCT2020	Neg/Neg/Unk	Fever New or increased cough New or increased muscle pain Headache#	Pos/
C4591001 1101 11011095 (USA/60/M)*	Placebo	Dose 2/20	02NOV2020		Neg/Neg/Neg	New or increased cough Nasal congestion# Runny nose#	Pos/
C4591001 1107 11071171 (USA/39/M)*	Placebo	Dose 2/58	10NOV2020		Neg/Neg/Neg	Fever Chills	Pos/
C4591001 1109 11091067 (USA/42/M)*	Placebo	Dose 2/84	11NOV2020		Neg/Neg/Neg	New or increased shortness of breath Sore throat	Pos/
C4591001 1109 11091092 (USA/18/M)*	Placebo	Dose 2/70	31OCT2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1109 11091323 (USA/64/M)*	Placebo	Dose 2/47	31OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/
C4591001 1109 11091416 (USA/46/F)*	Placebo	Dose 2/41	03NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/
C4591001 1109 11091448 (USA/46/F)*	Placebo	Dose 2/9	06OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/ (R1 Pos)
						New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1109 11091482 (USA/63/M)*	Placebo	Dose 2/28	29OCT2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1109 11091556 (USA/41/M)	Placebo	Dose 1/8	11OCT2020	16OCT2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1110 11101006 (USA/34/F)	BNT162b2 (30 µg)	Dose 1/2	01AUG2020	16AUG2020	Neg/Neg/Pos	New or increased cough Chills New loss of taste or smell Vomiting Headache#	Pos/
C4591001 1110 11101050 (USA/47/M)*	BNT162b2 (30 µg)	Dose 2/76	10NOV2020		Neg/Neg/Neg	New or increased cough Chills Sore throat	Pos/
C4591001 1110 11101072 (USA/42/M)	Placebo	Dose 2/4	28SEP2020		Neg/Neg/Pos	New loss of taste or smell Sore throat Diarrhea Fatigue# Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1110 11101136 (USA/62/M)*	Placebo	Dose 2/52	04NOV2020		Neg/Neg/Neg	New or increased cough Chills Diarrhea Fatigue# Headache# Runny nose#	Pos/
C4591001 1110 11101162 (USA/51/M)*	BNT162b2 (30 µg)	Dose 2/34	24OCT2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell Headache#	Pos/
C4591001 1110 11101229 (USA/46/F)	Placebo	Dose 1/18	27SEP2020	06OCT2020	Pos/Pos/Unk	Nasal congestion#	Pos/
C4591001 1111 11111010 (USA/75/M)*	Placebo	Dose 2/45	04OCT2020	05OCT2020	Neg/Neg/Neg	Fever Chills	Pos/
C4591001 1116 11161075 (USA/73/M)*	Placebo	Dose 2/43	03NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1116 11161253 (USA/61/M)	Placebo	Dose 1/8	25SEP2020	06OCT2020	Neg/Neg/Pos	Fever	Pos/
						New or increased cough	
						Chills	
						New or increased muscle pain	
C4591001 1116 11161322 (USA/23/M)	Placebo	Dose 2/7	20OCT2020		Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Chills	
						New or increased muscle pain	
						New loss of taste or smell	
						Sore throat	
C4591001 1117 11171010 (USA/72/F)*	Placebo	Dose 2/34	11OCT2020	19OCT2020	Neg/Neg/Neg	Fever	Pos/
						New or increased cough	
						Headache#	
C4591001 1118 11181088 (USA/73/M)*	Placebo	Dose 2/36	20OCT2020		Neg/Neg/Neg	New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1120 11201115 (USA/19/F)*	Placebo	Dose 2/73	06NOV2020		Neg/Neg/Neg	New or increased muscle pain Headache# Runny nose# Fever	Pos/
C4591001 1120 11201335 (USA/63/F)	Placebo	Dose 1/8	23OCT2020		Neg/Neg/Unk	New or increased muscle pain Sore throat Diarrhea Fatigue# Headache# Nasal congestion# Fever	Pos/
						New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea Fatigue#	

090177e1959af31\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1121 11211105 (USA/52/M)	Placebo	Dose 2/39	05NOV2020		Neg/Unk/Neg	Headache# Nasal congestion# Fever	Pos/
C4591001 1122 11221025 (USA/40/M)*	Placebo	Dose 2/32	01NOV2020		Neg/Neg/Neg	New or increased cough Sore throat Headache# Nasal congestion# Fever	Pos/
C4591001 1123 11231025 (USA/60/F)	Placebo	Dose 2/77	08NOV2020		Neg/Neg/Unk	New or increased cough Chills New or increased muscle pain Headache#	Pos/
C4591001 1123 11231073 (USA/25/F)*	Placebo	Dose 2/10	10SEP2020	06OCT2020	Neg/Neg/Neg	Sore throat Nasal congestion# New or increased cough Chills	Pos/Pos

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231085 (USA/20/M)	Placebo	Dose 1/4	16AUG2020	27AUG2020	Neg/Neg/Pos	New or increased muscle pain Sore throat Fatigue# Headache# Nasal congestion#	Pos/
C4591001 1123 11231086 (USA/35/F)*	Placebo	Dose 2/57	27OCT2020		Neg/Neg/Neg	New or increased muscle pain Headache#	Pos/
C4591001 1123 11231117 (USA/55/F)*	Placebo	Dose 2/64	10NOV2020		Neg/Neg/Neg	New or increased muscle pain Fatigue# Headache# Nasal congestion# Runny nose# Chills	Pos/
C4591001 1123 11231144 (USA/53/F)	BNT162b2 (30 µg)	Dose 1/9	28AUG2020	19SEP2020	Neg/Unk/Unk	New or increased muscle pain Fatigue# Fever	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231171 (USA/51/F)*	Placebo	Dose 2/49	02NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/
C4591001 1123 11231214 (USA/60/F)*	Placebo	Dose 2/34	26OCT2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat Fatigue# Headache# Nasal congestion# Runny nose#	Pos/
C4591001 1123 11231234 (USA/29/M)	Placebo	Dose 2/32	02NOV2020		Unk/Neg/Neg	New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231255 (USA/76/M)*	Placebo	Dose 2/20	24OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Headache# Nasal congestion# Runny nose#	Pos/ cough
C4591001 1123 11231256 (USA/72/F)*	Placebo	Dose 2/24	28OCT2020		Neg/Neg/Neg	Fatigue# Nasal congestion# Runny nose#	Pos/ cough
C4591001 1123 11231284 (USA/67/M)*	Placebo	Dose 2/12	24OCT2020		Neg/Neg/Neg	Fever	Pos/ New or increased cough Chills New or increased muscle pain Fatigue# Headache#

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1123 11231313 (USA/42/F)	Placebo	Dose 1/13	06OCT2020		Neg/Neg/Pos	Fever Chills New or increased muscle pain Nausea#	Pos/
C4591001 1123 11231386 (USA/33/F)	BNT162b2 (30 µg)	Dose 1/8	26OCT2020	03NOV2020	Neg/Neg/Pos	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1125 11251006 (USA/35/M)*	Placebo	Dose 2/42	11OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills	Pos/
C4591001 1125 11251014 (USA/45/F)*	Placebo	Dose 2/59	30OCT2020		Neg/Neg/Neg	Fever New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251023 (USA/49/M)*	Placebo	Dose 2/56	27OCT2020		Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Diarrhea Fatigue# New or increased cough	Pos/
C4591001 1125 11251028 (USA/39/F)*	Placebo	Dose 2/27	29SEP2020	02OCT2020	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Fatigue# Headache# Runny nose# Fever Chills New or increased muscle pain Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251049 (USA/52/M)*	Placebo	Dose 2/50	27OCT2020		Neg/Neg/Neg	New loss of taste or smell Sore throat Fatigue# Nasal congestion#	Pos/
C4591001 1125 11251107 (USA/69/M)	Placebo	Dose 2/3	22OCT2020		Neg/Neg/Neg	Fever Chills	Pos/
C4591001 1125 11251109 (USA/46/F)*	Placebo	Dose 2/51	04NOV2020		Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain Diarrhea Fatigue# Headache# Nasal congestion# Runny nose#	Pos/
C4591001 1125 11251114 (USA/59/M)*	Placebo	Dose 2/38	22OCT2020		Neg/Neg/Neg	Fever	Pos/Pos

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1125 11251124 (USA/39/M)*	Placebo	Dose 2/53	08NOV2020	10NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Headache#	Pos/
C4591001 1125 11251148 (USA/54/F)	BNT162b2 (30 µg)	Dose 1/13	14SEP2020	23SEP2020	Neg/Neg/Neg	New loss of taste or smell Fatigue#	Pos/
C4591001 1125 11251215 (USA/43/M)*	Placebo	Dose 2/25	06NOV2020		Neg/Neg/Neg	New or increased cough Headache# Nasal congestion#	Pos/
C4591001 1125 11251222 (USA/85/F)	BNT162b2 (30 µg)	Dose 1/6	02NOV2020		Neg/Neg/Unk	New or increased cough Fatigue# Runny nose#	Pos/
C4591001 1125 11251238 (USA/17/F)	Placebo	Dose 1/12	02NOV2020		Neg/Neg/Unk	New loss of taste or smell Fatigue# Headache# Nasal congestion# Runny nose#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1126 11261017 (USA/34/F)*	Placebo	Dose 2/50	20OCT2020		Neg/Neg/Neg	Fever	Pos/
C4591001 1127 11271099 (USA/23/F)	Placebo	Dose 1/21	08SEP2020	16SEP2020	Neg/Neg/Pos	New or increased muscle pain New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat Fatigue#	Pos/
C4591001 1128 11281165 (USA/26/F)*	Placebo	Dose 2/46	29OCT2020		Neg/Neg/Neg	New or increased cough Sore throat Headache#	Pos/
C4591001 1131 11311100 (USA/64/M)*	Placebo	Dose 2/58	12NOV2020		Neg/Neg/Neg	Fever Chills New or increased muscle pain New loss of taste or smell	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1131 11311138 (USA/45/F)*	Placebo	Dose 2/45	07NOV2020		Neg/Neg/Neg	Nasal congestion# New or increased cough	Pos/
C4591001 1133 11331209 (USA/30/M)*	Placebo	Dose 2/32	10OCT2020		Neg/Neg/Neg	New or increased shortness of breath Headache# Nasal congestion# New or increased cough	Pos/
C4591001 1133 11331512 (USA/36/M)	Placebo	Dose 1/17	11OCT2020		Neg/Neg/Unk	Sore throat Fatigue# Headache# Nasal congestion# Fever	Pos/
C4591001 1134 11341022 (USA/66/M)*	Placebo	Dose 2/29	29SEP2020	03OCT2020	Neg/Neg/Neg	New loss of taste or smell New or increased muscle pain	Pos/
C4591001 1135 11351148 (USA/35/M)	Placebo	Dose 2/3	10SEP2020	20SEP2020	Neg/Neg/Neg	Sore throat Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1135 11351207 (USA/33/F)*	Placebo	Dose 2/30	13OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat New or increased muscle pain	Pos/
C4591001 1141 11411020 (USA/29/M)	Placebo	Dose 2/6	29AUG2020	04SEP2020	Neg/Neg/Neg	New loss of taste or smell Diarrhea Fatigue# Headache# Nasal congestion# New or increased cough New or increased muscle pain Sore throat Fatigue#	Pos/
C4591001 1141 11411088 (USA/52/M)*	Placebo	Dose 2/29	07OCT2020		Neg/Neg/Neg	Fever Chills Sore throat Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1141 11411161 (USA/25/F)*	Placebo	Dose 2/47	08NOV2020		Neg/Neg/Neg	Runny nose# Fever	Pos/
						New or increased cough New or increased muscle pain Diarrhea Vomiting Headache# Nausea#	
C4591001 1141 11411162 (USA/20/M)*	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New or increased cough	Pos/
						Sore throat Fatigue# Headache#	
C4591001 1147 11471004 (USA/62/M)	Placebo	Dose 1/22	24AUG2020	28AUG2020	Neg/Neg/Unk	New or increased cough Sore throat Fatigue#	Pos/
C4591001 1147 11471035 (USA/52/M)	Placebo	Dose 1/18	23AUG2020	11SEP2020	Neg/Neg/Unk	New or increased cough Chills	Pos/Pos

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1147 11471037 (USA/74/F)	BNT162b2 (30 µg)	Dose 1/8	13AUG2020	20AUG2020	Unk/Pos/Pos	Sore throat Headache# Nasal congestion# Nasal congestion#	Pos/
C4591001 1149 11491066 (USA/40/M)	Placebo	Dose 1/13	24AUG2020	04SEP2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1149 11491113 (USA/69/M)*	BNT162b2 (30 µg)	Dose 2/44	23OCT2020	24OCT2020	Neg/Neg/Neg	New or increased cough Fatigue# Fever	Pos/
C4591001 1152 11521363 (USA/19/M)*	Placebo	Dose 2/9	06OCT2020		Neg/Neg/Neg	Chills Vomiting New or increased cough	Pos/
C4591001 1152 11521372 (USA/28/F)*	Placebo	Dose 2/32	29OCT2020		Neg/Neg/Neg	New or increased cough	Pos/
						Chills New or increased muscle pain Sore throat Headache#	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1156 11561006 (USA/45/M)	BNT162b2 (30 µg)	Dose 1/11	30AUG2020	01SEP2020	Neg/Pos/Neg	New or increased cough	Pos/Pos
C4591001 1156 11561033 (USA/55/F)	Placebo	Dose 1/11	05SEP2020	26SEP2020	Neg/Neg/Pos	New or increased cough New loss of taste or smell Headache# Nasal congestion#	Pos/
C4591001 1156 11561044 (USA/63/M)	Placebo	Dose 1/6	01SEP2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/
C4591001 1156 11561064 (USA/23/F)	BNT162b2 (30 µg)	Dose 1/7	04SEP2020	18SEP2020	Neg/Neg/Pos	Fever Chills New or increased muscle pain New loss of taste or smell	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1162 11621044 (USA/22/M)	BNT162b2 (30 µg)	Dose 1/5	10AUG2020		Neg/Unk/Pos	Diarrhea Nasal congestion# Runny nose# Fever	Pos/
C4591001 1162 11621075 (USA/40/F)*	Placebo	Dose 2/67	06NOV2020		Neg/Neg/Neg	Chills New loss of taste or smell Sore throat Headache# New or increased muscle pain	Pos/
C4591001 1163 11631113 (USA/25/M)*	Placebo	Dose 2/43	14OCT2020		Neg/Neg/Neg	Fatigue# Nausea# Fever	Pos/
C4591001 1163 11631135 (USA/42/M)*	Placebo	Dose 2/21	30SEP2020	02OCT2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1167 11671152 (USA/41/F)*	Placebo	Dose 2/26	20OCT2020		Neg/Neg/Neg	New or increased muscle pain Diarrhea Fever	Pos/Pos
C4591001 1167 11671157 (USA/58/M)*	Placebo	Dose 2/16	14OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Headache# Fever	Pos/
C4591001 1168 11681004 (USA/54/M)*	Placebo	Dose 2/67	07NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681007 (USA/33/F)*	Placebo	Dose 2/36	06OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Headache# New or increased cough	Pos/
C4591001 1168 11681008 (USA/37/M)*	Placebo	Dose 2/35	05OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat Fatigue# Headache# New or increased cough	Pos/
C4591001 1168 11681114 (USA/46/F)*	Placebo	Dose 2/23	13OCT2020		Neg/Neg/Neg	New loss of taste or smell Fatigue# Headache# Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1168 11681117 (USA/37/M)*	Placebo	Dose 2/45	04NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Headache# Fever	Pos/
C4591001 1168 11681226 (USA/24/F)	Placebo	Dose 1/12	19OCT2020	19OCT2020	Pos/Pos/Unk	New or increased muscle pain Headache#	Pos/
C4591001 1169 11691007 (USA/28/F)	Placebo	Dose 2/19	11OCT2020		Neg/Unk/Neg	New or increased shortness of breath New loss of taste or smell Fatigue#	Pos/
C4591001 1169 11691058 (USA/32/M)	Placebo	Dose 1/16	01OCT2020	11OCT2020	Neg/Neg/Pos	Fever New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1170 11701089 (USA/25/F)*	Placebo	Dose 2/16	01OCT2020		Neg/Neg/Neg	Chills Fever	Pos/
C4591001 1171 11711269 (USA/61/M)	Placebo	Dose 2/5	11OCT2020		Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1174 11741053 (USA/24/F)	Placebo	Dose 2/5	05OCT2020		Neg/Neg/Neg	Chills New loss of taste or smell	Pos/
C4591001 1178 11781065 (USA/48/M)*	Placebo	Dose 2/23	13OCT2020	25OCT2020	Neg/Neg/Neg	Headache# Nasal congestion# Fever	Pos/
C4591001 1178 11781118 (USA/56/M)	BNT162b2 (30 µg)	Dose 2/2	29SEP2020	29SEP2020	Neg/Neg/Pos	New or increased cough Chills New or increased muscle pain Sore throat Fatigue# Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1178 11781238 (USA/60/F)*	Placebo	Dose 2/16	29OCT2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat Headache#	Pos/
C4591001 1178 11781276 (USA/72/M)	BNT162b2 (30 µg)	Dose 2/7	27OCT2020		Neg/Neg/Unk	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat	Pos/
C4591001 1178 11781280 (USA/58/M)*	Placebo	Dose 2/9	03NOV2020		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1179 11791085 (USA/34/M)*	Placebo	Dose 2/34	09NOV2020		Neg/Neg/Neg	Sore throat Fatigue# Fever	Pos/
C4591001 1179 11791138 (USA/36/M)	BNT162b2 (30 µg)	Dose 1/8	31OCT2020		Neg/Neg/Unk	New or increased cough New or increased muscle pain Fever	Pos/
C4591001 1194 11941061 (DEU/51/M)	BNT162b2 (30 µg)	Dose 1/6	24OCT2020		Neg/Pos/Unk	New or increased cough New or increased muscle pain Sore throat New loss of taste or smell	Pos/Pos
C4591001 1203 12031037 (DEU/36/M)	BNT162b2 (30 µg)	Dose 1/6	26OCT2020	30OCT2020	Neg/Neg/Unk	Headache# Fever	Pos/
C4591001 1207 12071024 (TUR/43/M)	BNT162b2 (30 µg)	Dose 1/8	04NOV2020		Unk/Neg/Unk	New or increased cough Headache# Chills	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1209 12091013 (TUR/32/M)	BNT162b2 (30 µg)	Dose 1/6	07NOV2020	09NOV2020	Neg/Pos/Unk	New loss of taste or smell New loss of taste or smell Vomiting	Pos/
C4591001 1221 12211002 (USA/43/M)	Placebo	Dose 1/20	01NOV2020		Neg/Neg/Unk	Chills	Unk/Pos
C4591001 1223 12231005 (USA/20/F)*	Placebo	Dose 2/51	06NOV2020		Neg/Neg/Neg	Vomiting New or increased cough	Pos/
C4591001 1223 12231096 (USA/77/F)*	Placebo	Dose 2/48	11NOV2020	12NOV2020	Neg/Neg/Neg	Chills Sore throat New or increased cough	Pos/
C4591001 1226 12261309 (BRA/61/M)*	Placebo	Dose 2/40	20OCT2020	26OCT2020	Neg/Neg/Neg	Chills Headache# New or increased cough	Pos/
C4591001 1226 12261360 (BRA/26/M)	Placebo	Dose 2/1	11SEP2020		Neg/Neg/Pos	New or increased cough New loss of taste or smell	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261363 (BRA/48/F)*	Placebo	Dose 2/23	03OCT2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Vomiting	Pos/
C4591001 1226 12261599 (BRA/41/F)*	BNT162b2 (30 µg)	Dose 2/36	06NOV2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/
C4591001 1226 12261624 (BRA/52/M)*	Placebo	Dose 2/34	02NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Runny nose#	Pos/
C4591001 1226 12261660 (BRA/27/F)*	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12261894 (BRA/28/M)	Placebo	Dose 1/5	29SEP2020	02OCT2020	Neg/Neg/Pos	New or increased muscle pain Headache# Fever	Pos/
C4591001 1226 12261964 (BRA/27/F)*	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	Chills New or increased muscle pain New or increased cough	Pos/
C4591001 1226 12262108 (BRA/49/F)	Placebo	Dose 1/20	27OCT2020		Neg/Neg/Unk	Chills New or increased muscle pain New loss of taste or smell Sore throat Nasal congestion# Headache#	Pos/
C4591001 1226 12262111 (BRA/51/M)*	Placebo	Dose 2/12	10NOV2020	12NOV2020	Neg/Neg/Neg	Nasal congestion# Fever Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1226 12262189 (BRA/22/M)	Placebo	Dose 1/14	27OCT2020	01NOV2020	Neg/Neg/Unk	New or increased cough Headache#	Pos/
C4591001 1226 12262235 (BRA/71/M)	BNT162b2 (30 µg)	Dose 1/21	05NOV2020	09NOV2020	Neg/Neg/Unk	Headache#	Pos/
C4591001 1226 12262267 (BRA/27/F)	Placebo	Dose 1/2	18OCT2020		Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12311043 (ARG/46/M)*	Placebo	Dose 2/40	10OCT2020	11OCT2020	Neg/Neg/Neg	New or increased cough Chills Headache#	Pos/
C4591001 1231 12311054 (ARG/37/M)	Placebo	Dose 1/8	18AUG2020	18AUG2020	Neg/Neg/Unk	Fever	Pos/
C4591001 1231 12311087 (ARG/44/M)	Placebo	Dose 1/15	26AUG2020	15SEP2020	Neg/Neg/Pos	Fever New or increased cough New or increased muscle pain New loss of taste or smell Diarrhea Vomiting Nausea#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311147 (ARG/31/M)	Placebo	Dose 1/5	17AUG2020	30AUG2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Runny nose#	Pos/
C4591001 1231 12311195 (ARG/53/M)	Placebo	Dose 1/16	29AUG2020	10OCT2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1231 12311267 (ARG/67/M)*	Placebo	Dose 2/24	26SEP2020	07OCT2020	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/
C4591001 1231 12311356 (ARG/30/F)	Placebo	Dose 1/17	31AUG2020	18SEP2020	Neg/Neg/Unk	New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1231 12311391 (ARG/28/F)	Placebo	Dose 1/10	24AUG2020		Neg/Neg/Unk	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12311407 (ARG/63/M)*	Placebo	Dose 2/24	27SEP2020	06OCT2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311431 (ARG/21/M)	Placebo	Dose 1/3	17AUG2020	07SEP2020	Neg/Neg/Unk	Diarrhea Headache# Fever	Pos/
C4591001 1231 12311531 (ARG/35/M)*	Placebo	Dose 2/9	16SEP2020	27SEP2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12311532 (ARG/50/M) µg)	BNT162b2 (30	Dose 1/8	23AUG2020	25AUG2020	Neg/Neg/Pos	New or increased shortness of breath New or increased muscle pain Fatigue# Runny nose# Fever	Pos/
C4591001 1231 12311549 (ARG/58/F)	Placebo	Dose 1/13	28AUG2020	13SEP2020	Neg/Neg/Pos	New or increased cough Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311556 (ARG/24/M)*	Placebo	Dose 2/45	21OCT2020	09NOV2020	Neg/Neg/Neg	New loss of taste or smell Headache# Runny nose# New loss of taste or smell	Pos/
C4591001 1231 12311560 (ARG/44/M)*	Placebo	Dose 2/70	12NOV2020		Neg/Neg/Neg	Headache# Nasal congestion# Fever	Pos/
C4591001 1231 12311568 (ARG/43/M)	Placebo	Dose 1/6	21AUG2020	10SEP2020	Neg/Neg/Pos	New or increased cough New or increased muscle pain	Pos/
C4591001 1231 12311641 (ARG/25/M) µg)	BNT162b2 (30 µg)	Dose 1/10	25AUG2020	15SEP2020	Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12311651 (ARG/52/F)*	Placebo	Dose 2/8	14SEP2020	01OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311656 (ARG/20/F)	Placebo	Dose 1/24	08SEP2020	20SEP2020	Neg/Neg/Pos	Vomiting Headache# New or increased muscle pain	Pos/
C4591001 1231 12311664 (ARG/34/F)*	Placebo	Dose 2/9	15SEP2020	03OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1231 12311754 (ARG/54/M)*	Placebo	Dose 2/38	14OCT2020	25OCT2020	Neg/Neg/Neg	New or increased cough Fever	Pos/
C4591001 1231 12311764 (ARG/34/M)*	Placebo	Dose 2/63	09NOV2020	09NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat New loss of taste or smell	Pos/
C4591001 1231 12311911 (ARG/41/F)	BNT162b2 (30 µg)	Dose 1/8	25AUG2020	30AUG2020	Neg/Neg/Neg	Nasal congestion# New or increased muscle pain Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12311982 (ARG/41/F)*	Placebo	Dose 2/37	14OCT2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/
C4591001 1231 12312130 (ARG/64/F)	Placebo	Dose 1/3	20AUG2020	27AUG2020	Neg/Pos/Neg	Fever New or increased cough Sore throat Headache#	Pos/
C4591001 1231 12312320 (ARG/51/F)	Placebo	Dose 1/61	18OCT2020		Neg/Neg/Unk	New or increased cough New loss of taste or smell Fatigue# Headache#	Pos/
C4591001 1231 12312334 (ARG/40/F)	Placebo	Dose 1/15	02SEP2020		Neg/Neg/Pos	New loss of taste or smell	Pos/
C4591001 1231 12312339 (ARG/22/F)	BNT162b2 (30 µg)	Dose 1/6	24AUG2020	23SEP2020	Neg/Neg/Neg	New loss of taste or smell Runny nose#	Pos/
C4591001 1231 12312375 (ARG/43/F)	BNT162b2 (30 µg)	Dose 1/9	27AUG2020	07SEP2020	Neg/Neg/Pos	New loss of taste or smell Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312479 (ARG/43/M)*	Placebo	Dose 2/30	09OCT2020		Neg/Neg/Neg	Vomiting Headache# New or increased cough	Pos/
C4591001 1231 12312507 (ARG/47/F)*	Placebo	Dose 2/10	17SEP2020	28SEP2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Nasal congestion# New or increased muscle pain	Pos/
C4591001 1231 12312571 (ARG/62/M)	Placebo	Dose 1/13	01SEP2020	13SEP2020	Neg/Neg/Pos	Sore throat Runny nose# Fever	Pos/
C4591001 1231 12312630 (ARG/39/F)*	Placebo	Dose 2/44	23OCT2020		Neg/Neg/Neg	New or increased cough Headache# Fever New or increased cough	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312635 (ARG/71/M)*	Placebo	Dose 2/27	04OCT2020		Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12312660 (ARG/35/M)	Placebo	Dose 1/23	11SEP2020	23SEP2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Nasal congestion# New or increased cough	Pos/
C4591001 1231 12312679 (ARG/32/M)	Placebo	Dose 2/4	14SEP2020	14NOV2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/
C4591001 1231 12312752 (ARG/36/M)	Placebo	Dose 1/17	06SEP2020	24SEP2020	Neg/Neg/Pos	New or increased cough Diarrhea Fatigue# Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12312763 (ARG/43/F)	Placebo	Dose 1/19	08SEP2020		Neg/Neg/Pos	New or increased cough Headache# New or increased cough New loss of taste or smell Headache# Runny nose#	Pos/
C4591001 1231 12312805 (ARG/33/M) µg)	BNT162b2 (30	Dose 1/17	06SEP2020	08SEP2020	Neg/Pos/Neg	New or increased cough	Pos/
C4591001 1231 12312867 (ARG/40/F)*	Placebo	Dose 2/35	14OCT2020	01NOV2020	Neg/Neg/Neg	Fever New loss of taste or smell Diarrhea Headache#	Pos/
C4591001 1231 12312914 (ARG/50/M)*	Placebo	Dose 2/43	26OCT2020		Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain Sore throat	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313006 (ARG/50/F)	BNT162b2 (30 µg)	Dose 1/2	22AUG2020	30AUG2020	Neg/Pos/Pos	Fatigue# Headache# Fever	Pos/
C4591001 1231 12313068 (ARG/41/M)	Placebo	Dose 1/5	26AUG2020	31AUG2020	Neg/Neg/Pos	Chills Sore throat New or increased muscle pain	Pos/
C4591001 1231 12313069 (ARG/36/M)	Placebo	Dose 1/9	30AUG2020	19SEP2020	Neg/Neg/Pos	New loss of taste or smell New or increased cough New or increased muscle pain New loss of taste or smell Sore throat Headache# Runny nose#	Pos/
C4591001 1231 12313090 (ARG/57/M)	Placebo	Dose 1/13	03SEP2020	28SEP2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12313103 (ARG/73/M)	Placebo	Dose 1/10	31AUG2020	10SEP2020	Neg/Neg/Pos	New or increased shortness of breath Fever	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313125 (ARG/48/M)	Placebo	Dose 1/76	05NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Diarrhea Headache# Fever	Pos/
C4591001 1231 12313182 (ARG/33/M)*	Placebo	Dose 2/10	20SEP2020	19OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased shortness of breath	Pos/
C4591001 1231 12313225 (ARG/55/F)	BNT162b2 (30 µg)	Dose 1/3	24AUG2020	24AUG2020	Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12313296 (ARG/49/F)*	Placebo	Dose 2/25	04OCT2020	20OCT2020	Neg/Neg/Neg	New loss of taste or smell Fatigue# Headache# New or increased cough	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313357 (ARG/31/M)	BNT162b2 (30 µg)	Dose 1/3	25AUG2020	30AUG2020	Neg/Neg/Pos	New loss of taste or smell Fever	Pos/
C4591001 1231 12313395 (ARG/39/M)	Placebo	Dose 1/2	24AUG2020	31AUG2020	Neg/Pos/Pos	New loss of taste or smell	Pos/
C4591001 1231 12313400 (ARG/46/M)*	Placebo	Dose 2/37	19OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1231 12313422 (ARG/34/M)*	Placebo	Dose 2/44	28OCT2020		Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Sore throat Fever	Pos/
C4591001 1231 12313457 (ARG/60/M)	Placebo	Dose 1/5	27AUG2020	18SEP2020	Unk/Neg/Pos	New or increased cough New or increased shortness of breath Diarrhea Headache# Fever	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313510 (ARG/29/F)	Placebo	Dose 1/13	04SEP2020	07SEP2020	Unk/Neg/Pos	New or increased cough New or increased muscle pain Fatigue# Fever	Pos/
C4591001 1231 12313520 (ARG/28/F)*	Placebo	Dose 2/8	22SEP2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased cough	Pos/
C4591001 1231 12313657 (ARG/48/F)	Placebo	Dose 1/11	03SEP2020	18SEP2020	Neg/Neg/Pos	New loss of taste or smell Sore throat Fatigue# Nasal congestion# Chills	Pos/
C4591001 1231 12313662 (ARG/27/M) µg)	BNT162b2 (30	Dose 1/8	31AUG2020	10SEP2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Headache# New or increased cough	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12313668 (ARG/33/M)*	Placebo	Dose 2/12	24SEP2020	02OCT2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea Headache# New loss of taste or smell	Pos/
C4591001 1231 12313709 (ARG/38/M)	BNT162b2 (30 µg)	Dose 1/14	06SEP2020	03OCT2020	Neg/Neg/Neg	Sore throat New loss of taste or smell Sore throat	Pos/
C4591001 1231 12313787 (ARG/58/M)*	Placebo	Dose 2/48	02NOV2020	05NOV2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 1231 12313895 (ARG/50/F)*	Placebo	Dose 2/21	03OCT2020	17OCT2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/
C4591001 1231 12314112 (ARG/52/M)*	Placebo	Dose 2/42	28OCT2020	02NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314301 (ARG/56/M)	BNT162b2 (30 µg)	Dose 1/4	29AUG2020	30SEP2020	Neg/Neg/Pos	New or increased muscle pain New loss of taste or smell Fatigue# Headache# Nasal congestion#	Pos/
C4591001 1231 12314308 (ARG/31/F)*	Placebo	Dose 2/15	30SEP2020	11OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Vomiting Fatigue#	Pos/
C4591001 1231 12314314 (ARG/33/F)	BNT162b2 (30 µg)	Dose 1/2	27AUG2020	29AUG2020	Neg/Pos/Unk	Fever	Pos/
C4591001 1231 12314477 (ARG/36/M)	Placebo	Dose 2/16	03OCT2020	15OCT2020	Pos/Neg/Neg	New or increased cough New loss of taste or smell	Pos/
C4591001 1231 12314492 (ARG/23/F)	Placebo	Dose 1/2	28AUG2020	09SEP2020	Neg/Pos/Pos	Fever New or increased cough	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314534 (ARG/18/F)*	Placebo	Dose 2/21	05OCT2020	09OCT2020	Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell Headache# New or increased cough	Pos/
C4591001 1231 12314622 (ARG/32/F)*	Placebo	Dose 2/15	01OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Headache#	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1231 12314700 (ARG/43/M)	BNT162b2 (30 µg)	Dose 1/7	03SEP2020	04OCT2020	Neg/Neg/Neg	Fever	Pos/
C4591001 1231 12315636 (ARG/53/F)*	Placebo	Dose 2/35	23OCT2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/
C4591001 1231 12315637 (ARG/40/F)*	Placebo	Dose 2/11	29SEP2020	08OCT2020	Neg/Neg/Neg	Sore throat Headache# Fever	Pos/
C4591001 1235 12351027 (USA/50/M)	Placebo	Dose 1/18	23SEP2020	03OCT2020	Neg/Neg/Unk	Chills New or increased muscle pain New loss of taste or smell Fever	Pos/
						New or increased cough New or increased shortness of breath Chills Vomiting	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1235 12351071 (USA/50/M)	Placebo	Dose 1/8	21SEP2020	25SEP2020	Neg/Neg/Unk	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/
C4591001 1235 12351093 (USA/30/F)*	BNT162b2 (30 µg)	Dose 2/32	08NOV2020	14NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/
C4591001 1235 12351187 (USA/23/F)	Placebo	Dose 1/8	23OCT2020		Neg/Neg/Unk	Fever New or increased cough Sore throat Headache# Nasal congestion#	Pos/
C4591001 1235 12351188 (USA/36/F)	BNT162b2 (30 µg)	Dose 1/6	21OCT2020		Neg/Neg/Unk	Chills Headache# Runny nose#	Pos/
C4591001 1241 12411260 (BRA/39/M)	Placebo	Dose 1/12	30AUG2020	13SEP2020	Neg/Neg/Unk	New or increased muscle pain	Pos/

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1241 12411688 (BRA/29/M)	Placebo	Dose 1/13	27SEP2020	15OCT2020	Neg/Neg/Pos	New loss of taste or smell Headache# New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/Pos
C4591001 1241 12411695 (BRA/44/F)	Placebo	Dose 1/4	18SEP2020	05OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/
C4591001 1241 12411885 (BRA/23/M) µg)	BNT162b2 (30	Dose 2/14	22OCT2020	24OCT2020	Pos/Neg/Neg	Runny nose# Sore throat	Pos/Neg
C4591001 1241 12412017 (BRA/59/M)*	Placebo	Dose 2/9	29OCT2020		Neg/Neg/Neg	Fever	Pos/Pos

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1241 12412018 (BRA/55/F)*	Placebo	Dose 2/8	28OCT2020		Neg/Neg/Neg	New or increased muscle pain Headache# Runny nose# Fever	Pos/Pos
C4591001 1241 12412215 (BRA/39/M)	Placebo	Dose 2/3	06NOV2020		Neg/Neg/Pos	Sore throat Fever	Pos/
C4591001 1241 12412355 (BRA/38/F)	Placebo	Dose 1/3	21OCT2020	04NOV2020	Neg/Neg/Pos	Chills New or increased muscle pain New loss of taste or smell New loss of taste or smell	Pos/
C4591001 1241 12412568 (BRA/60/F)	Placebo	Dose 1/7	10NOV2020		Unk/Neg/Unk	Diarrhea Headache# Runny nose# Fever	Unk/Pos
						New or increased cough Vomiting	

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 1247 12471066 (ZAF/58/F)	Placebo	Dose 1/17	15OCT2020		Neg/Neg/Unk	New or increased cough New or increased shortness of breath	Pos/
C4591001 1247 12471085 (ZAF/54/F)	Placebo	Dose 2/12	30OCT2020	03NOV2020	Neg/Unk/Neg	New or increased cough Chills Diarrhea	Pos/
C4591001 1251 12511159 (USA/37/F)*	Placebo	Dose 2/26	26OCT2020	29OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/
C4591001 1251 12511207 (USA/48/M)	Placebo	Dose 1/3	25SEP2020	29SEP2020	Neg/Neg/Pos	New or increased cough Fatigue#	Pos/
C4591001 1251 12511209 (USA/62/M)	Placebo	Dose 2/7	19OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/
C4591001 4444 44441025 (ARG/51/M)	Placebo	Dose 1/8	28SEP2020	05OCT2020	Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441043 (ARG/54/M)	BNT162b2 (30 µg)	Dose 1/14	04OCT2020	12OCT2020	Neg/Neg/Neg	Headache#	Pos/
C4591001 4444 44441044 (ARG/35/F)	Placebo	Dose 1/13	03OCT2020	10OCT2020	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/
C4591001 4444 44441092 (ARG/64/M)*	Placebo	Dose 2/23	03NOV2020		Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat Headache#	Pos/
C4591001 4444 44441144 (ARG/38/M)*	Placebo	Dose 2/26	07NOV2020		Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell Diarrhea	Pos/
C4591001 4444 44441204 (ARG/59/F)*	BNT162b2 (30 µg)	Dose 2/21	02NOV2020		Neg/Neg/Neg	New or increased muscle pain	Pos/

090177e1959af311\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
C4591001 4444 44441224 (ARG/52/M)*	Placebo	Dose 2/13	25OCT2020		Neg/Neg/Neg	New loss of taste or smell Fever	Pos/
C4591001 4444 44441253 (ARG/49/M)	Placebo	Dose 1/5	25SEP2020	09OCT2020	Pos/Neg/Neg	New or increased shortness of breath New or increased muscle pain New or increased cough	Pos/
C4591001 4444 44441560 (ARG/38/F)	Placebo	Dose 1/7	29SEP2020	07OCT2020	Neg/Neg/Pos	Sore throat New or increased muscle pain	Pos/
C4591001 4444 44441563 (ARG/38/M)*	Placebo	Dose 2/8	21OCT2020		Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/
C4591001 4444 44441787 (ARG/62/M)	Placebo	Dose 1/4	26SEP2020	27SEP2020	Pos/Neg/Neg	Diarrhea Headache# New or increased cough	Pos/
C4591001 4444 44442188 (ARG/24/M) µg)	BNT162b2 (30	Dose 1/9	05OCT2020		Neg/Pos/Pos	New or increased cough	Pos/
C4591001 4444 44442304 (ARG/49/M)	Placebo	Dose 2/12	26OCT2020	11NOV2020	Neg/Neg/Neg	New or increased muscle pain	Pos/

090177e1959af31\Final\Final On: 24-Nov-2020 13:48 (GMT)

16.2.8.5 Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms, Including CDC-Defined Symptoms – Dose 1 All-Available Efficacy Population

Subject (Country/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b)
						New loss of taste or smell	
						Sore throat	

Abbreviations: ARG = Argentina; BRA = Brazil; DEU = Germany; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein–binding; Neg = negative; Pos = positive; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown; ZAF = South Africa.

Note: * indicates subject in the evaluable efficacy (7 days) population with first COVID-19 occurrence from 7 days after Dose 2 and without evidence of infection prior to 7 days after Dose 2.

Note: # indicates subjects with additional CDC-defined symptoms.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

Note: † = HIV-positive subject.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (16:08) Source Data: adsympt Table Generation: 18NOV2020 (21:18)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_Efficacy_FA_164/adsympt_1001_sympt_cdc_d1_aai